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Abstract
Although frequently cured of Hodgkin lymphoma, adolescents and young adults can develop
radiation induced second cancers. These patients could potentially benefit from scanned
ion radiotherapy yet likely would require motion mitigation strategies. In theory, fourdimensional (4D) optimization of ion beam fields for individual motion states of respiration
can enable superior sparing of healthy tissue near moving targets, compared to other motion
mitigation strategies. Furthermore, carbon-ion therapy can sometimes provide greater
relative biological effectiveness (RBE) for cell sterilization in a target but nearly equivalent
RBE in tissue upstream of the target, compared to proton therapy. Thus, we expected that
for some patients with Hodgkin lymphoma, carbon-ion therapy would reduce the predicted
risk of second cancer incidence in the breast compared with proton therapy.
The purpose of this work was to determine whether 4D-optimized carbon-ion therapy
would significantly reduce the predicted risk of radiation induced second cancers in the
breast for female Hodgkin lymphoma patients while preserving tumor control compared
with proton therapy. To achieve our goals, we first investigated whether 4D-optimized carbon beam tracking could reduce dose to volumes outside a moving target compared with
3D-optimized carbon beam tracking while preserving target dose coverage. To understand
the reliability of scanned carbon beam tracking, we studied the robustness of dose distributions in thoracic targets to uncertainties in patient motion. Finally, we investigated
whether using carbon-ion therapy instead of proton therapy would significantly reduce the
predicted risk of second cancer in the breast for a sample of Hodgkin lymphoma patients.
We found that 4D-optimized ion beam tracking therapy can reduce the maximum dose
to critical structures near a moving target by as much as 53%, compared to 3D-optimized
ion beam tracking therapy. We validated these findings experimentally using a scanned
carbon ion synchrotron and a motion phantom. We found scanned carbon beam tracking
to be sensitive to a number of motion uncertainties, most notably phase delays in tracking,
systematic spatial errors, and interfractional motion changes. Our findings indicate that a
lower risk of second cancer in the breast might be expected for some Hodgkin lymphoma
patients using carbon-ion therapy instead of proton therapy. For our reference scenario,
we found the ratio of risk to be 0.77 ± 0.35 for radiogenic breast cancer after carbon-ion
therapy versus proton therapy. Our findings were dependent on the RBE values for tumor
induction and the radiosensitivity of breast tissue, as well as the physical dose distribution.

xi

Chapter 1
Introduction
1.1

Goal of Radiotherapy

Since the discovery of radioactivity and x-rays in the late 1890s, scientists and medical
doctors have worked together to harness the energy of ionizing radiation to diagnose and
treat patients. For many patients, radiotherapy offers a localized or regionalized, minimally
invasive treatment option, which can sterilize diseased cells. Radiotherapy is routinely used
today to treat cancer patients, and roughly 50% of all cancer patients will receive radiotherapy during some phase of their treatment, which may also include surgery, chemotherapy,
and other treatment. In particular, radiation may be beneficial when surgical resection of
the diseased tissue is not possible, for example, due to the presence of critical structures
near the tumors, the inability of the patient to undergo anesthesia, or due to undesired
functional or cosmetic side effects of surgery.
Whereas surgery can, in principle, remove the entire tumor and with it every single
cell of cancer from the patient, radiotherapy, as a primary treatment, functions more on the
basis of stochastic probability, that is, a certain dose of radiation will sterilize cancer cells in
the radiation field with a given probability. Even when treatment is delivered “perfectly”
and the radiation strikes every cell of cancer in the patient, a non-zero probability will
always exist that a cancer cell survives the irradiation and can possibly seed another tumor.
Increasing the dose of radiation reduces this probability for most cancers but increases the
damage to healthy tissues in or near the radiation field. Fortunately, cancer cells are
often more susceptible to radiation damage than healthy tissue cells, and thus a prescribed
radiation dose can deliver both lethal damage to the cancer cells and sublethal damage
to healthy tissue, which can often be repaired by the healthy cells. Unfortunately, side
effects of radiation therapy can be devastating, including radiogenic second cancer, cardiac
toxicity, lung fibrosis, esophageal fibrosis, tissue necrosis, skin desquamation, and loss of
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fertility, among others (Marks et al., 2010). For these reasons, radiation doses are kept as
low as possible, and the main research problem posed to scientists in radiation oncology
during the last century has been: How do we sterilize the most cancer cells and preserve
the most healthy tissue for these patients?

1.2

Physical Principles of Ion Radiotherapy

Particle Selection
Most radiation treatments are currently delivered by external beam photon radiation,
for example, 6 MV x-ray beams, but other radiation fields are also used clinically, such as
electrons, neutrons, protons, and carbon ions. Ion radiotherapy using protons or carbon
ions offers theoretical advantages for many patients compared with photon therapy but
presently requires an immense financial investment, that is, hundreds of millions of dollars,
to build and maintain the treatment facility. Nonetheless, there is increasing construction
worldwide of new proton facilities and, to a lesser degree, new carbon ion facilities. To
illustrate the theoretical benefit of ion therapy, a comparison of physical dose distributions
as a function of depth in water for various radiation beams is shown in Figure 1.1. To further
illustrate the physical differences between photon therapy and ion therapy, treatment plans
are shown for a spherical target in water in Figure 1.2 for 18 MV photon beams and 200
MeV passively scattered proton beams.
Due to the physical energy loss characteristics of charged particles stopping in matter,
ion beams are particularly promising for treating deep tumors while sparing large volumes of
normal tissue both upstream and downstream of the tumor. The two physical phenomena
that most influence the shape of the dose distribution in ion radiotherapy are inelastic
collisions with atomic electrons and elastic scattering with atomic nuclei, both governed by
the electromagnetic force.
Energy Loss of Ions via Inelastic Collisions
Uncharged radiations, e.g., photons and neutrons, mainly pass unperturbed through
free space in matter, occasionally colliding with nuclei or orbital electrons. In contrast,
charged particles, like protons or carbon ions, quasi-continuously lose energy via inelastic
Coulomb collisions with atomic electrons in matter, leaving a wake of ionized and excited
atoms in their path.
The energy loss of ion projectiles per unit pathlength in an absorber (−dE/dx) is
2

1
Photon
18 MV

Proton
130 MeV

Dose (relative)

0.8

Carbon Ion
300 MeV

Electron
20 MeV

0.6

0.4

0.2

0

0

5

10
Depth (cm)

15

20

Figure 1.1: Absorbed dose distributions as a function of depth in water shown for various
clinical radiation beams. The 18 MV photon dose distribution (black curve) exhibits an
initial rise in dose at shallow depths, as the photons produce cascades of secondary electrons,
followed by an exponential attenuation of dose at increasing depth as the primary photons
are removed from the beam. The 20 MeV electron beam (orange curve) provides a fairly
flat high dose region at shallow depths that falls off as electrons reach the end of their range.
An exit dose “tail” is seen on the electron distribution due to the production of secondary
Bremsstrahlung photons. Both 130 MeV proton (red curve) and 300 MeV carbon ion (blue
curve) beams provide an inverted depth-dose profile that reaches a sharp maximum, termed
the “Bragg peak”, near the end of the particle range. An exit dose “tail” is also seen on
the carbon ion distribution due to fragmentation of the carbon projectiles, which results
in lower-z fragment projectiles having a longer range in water. The depth-dose profile seen
for the proton and carbon ion beams may be utilized to treat deeper targets while sparing
healthy tissue both upstream of the target and downstream of the target.

3

Photon

Proton

(a)

(b)

(c)

(d)

Figure 1.2: Comparison of dose distributions for 18 MV photon (left) and 200 MeV proton
(right) radiotherapy for a 5-cm spherical target in water (depth of 150 mm). All plans were
normalized to provide 1 Gy to the center of the target (white circle) using: (a) a single
photon field, (b) a single proton field, (c) 4 photon fields, and (d) 4 proton fields. Beam
directions are indicated by red arrows. For the single field plans (a and b), the proton field
deposits much less dose in the volumes both upstream of the target and downstream of the
target, compared with the photon field. Increasing the number of beam angles to 4 (c and
d) can reduce the dose magnitude to volumes outside of the target but increases the total
volume exposed to radiation.
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described theoretically by the Bethe-Bloch Equation (Leo, 1994), which is valid for relativistic particle velocities greater than approximately one-tenth of the speed of light, such
as are commonly used in radiotherapy,


2
2me c2 γ 2 β 2 Wmax
C
dE
2
2 Z z
2
= 2πNa re me c ρ
ln(
,
) − 2β − δ − 2
−
dx
A β2
I2
Z

(1.1)

where Na is Avogadro’s number, re is the classical electron radius, me c2 is the rest mass
energy of an electron, ρ is the mass density of an absorber, Z is the atomic number of
the absorber, A is the atomic mass of the absorber, z is the charge of the ion projectile,
β is the velocity of the projectile, as a fraction of the speed of light in vacuum, γ is the
Lorentz factor, Wmax is the maximum energy transfer by a head-on collision with a single
electron, I is the mean excitation potential of the absorber, δ is a“density correction” factor
to account for polarization of the absorber by the projectile, and C is a “shell correction”
factor to account for the influence of dynamic electron fields near the projectile, which is
more important at lower velocities.
The inverse relation between energy loss and the projectile velocity (−dE/dx ∝ 1/β 2 )
explains the inverted depth dose profile and the characteristic “Bragg peak” as the projectile
slows down and stops in matter, seen for the proton beam and carbon ion beam in Figure
1.1. Conceptually, slower ions have more time to perturb the local orbital electrons in the
absorber whereas faster ions pass through the local environment quickly, with less time to
exert force on local orbital electrons.
Elastic Scattering of Ions
Whereas inelastic collisions with orbital electrons are the main mechanism of energy
loss and most responsible for the shape of the depth dose distribution for ion beams along
the depth axis, elastic scattering with atomic nuclei is most responsible for the shape of
the off-axis or lateral dose distribution. The degree of elastic scattering is fundamentally
described by Rutherford scattering, i.e., the charged projectile is deflected as it passes
through the electric field of a positively charged nucleus in the absorber. The differential
scattering cross section (dσ) for a projectile scattering into a given solid angle (dΩ) about
an angle (θ) from its initial trajectory is given by (Leo, 1994)
(me c/βp)2
dσ
= z 2 Z 2 re2
dΩ
4sin4 (θ/2)
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(1.2)

The degree of scattering is seen here to be directly proportional to the square of the projectile charge z 2 and inversely proportional to the square of the projectile velocity β 2 and
momentum p2 . The many individual Rutherford scattering events that influence a single
projectile path can be described by multiple Coulomb scattering theory, which predicts the
lateral and angular probability distributions of a particle beam that undergoes many elastic scattering events after traversing a given thickness of matter (Rossi and Greisen, 1941).
Ultimately, these theories can be used to predict the shape of dose distributions from ion
beams in patients, an important requirement for radiotherapy treatment planning.
One important principle regarding elastic scattering for radiotherapy is that higher z
particles typically require higher velocity than lighter particles to achieve the same range in
matter and, despite their higher charge, are less influenced by elastic Coulomb scattering
due to their higher momentum. Thus, for heavier ions, e.g., carbon ions versus protons, it
is usually possible to deliver a beam with sharper definition at depth in the patient. Weber
and Kraft (2009) reported that carbon dose gradients in the lateral beam penumbra can
be approximately 3 times sharper than those of protons, which can reduce dose to healthy
tissues near the target. This is especially important when critical structures are very near
the lateral edge of a target boundary and is a major impetus to use carbon ions instead of
protons or electrons.
Beam Delivery Systems for Ion Therapy
In order to deliver a therapeutic beam that is useful for patients with a wide range
of tumor sizes, a system must be implemented to spread the Bragg peak to cover the
three-dimensional (3D) extent of the tumor. The two most common delivery systems for
ion therapy are passive scattering and active scanning, illustrated in Figure 1.3. Both of
these systems are capable of spreading the Bragg peak over a 3D tumor volume. The
passively scattered system has the advantage that the beam is delivered to the entire
treatment volume almost instantaneously but the disadvantages that the dose distribution is
generally not conformal to both the proximal and distal surfaces of the target. Furthermore,
heterogeneities in the patient may introduce dose heterogeneity in the passively scattered
ion dose distribution due to lateral scatter disequilibrium. The actively scanned system
potentially improves the conformity and uniformity of dose to a target but has a high
sensitivity to uncertainties in patient setup and motion, since the individual ion scan paths
can potentially overlap or miss regions of the target when the patient is misaligned or moves
during treatment.
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Figure 1.3: Comparison of passively scattered ion beam delivery system versus an actively
scanned ion beam delivery system. Initially, a narrow diameter (few mm) ion beam is
produced by a particle accelerator, e.g., synchrotron or cyclotron. In order to produce a
useful therapeutic beam, the narrow beam and sharp Bragg peak must be spread to cover
the lateral extent and depth variation of a 3D target volume in a patient. The passively
scattered system (left) uses a range-modulation wheel, e.g., a spinning disk of acrylic with
variable thickness, to quickly scan the ion beam over the depth-thickness of the target,
producing a spread-out Bragg peak. A scattering foil is used to spread the pencil beam
into a broad field, which is then collimated to match the lateral boundary of the target. A
range compensator modulates the range of the broad ion beam to match the off-axis distal
depth of the target surface, providing a target dose (red region) that is conformal to the
distal target surface but not conformal to the proximal target surface, giving unwanted
dose upstream of the target. In contrast, an actively scanned beam delivery system (right)
uses magnetic deflection to scan the ion pencil beam across the lateral extent of the target.
The beam typically stops at prescribed spots (small circles) throughout the target and
delivers a prescribed number of ions. After a single iso-energy layer is finished, the energy
of the pencil beam is actively changed, e.g., by resetting the acceleration scheme, and all
other iso-energy layers are delivered to provide dose to all depths of the target (see filled
small red circles at right). The advantages of an actively scanned delivery system include
the ability to conform dose to both the deep and shallow surfaces of the target and the
ability to optimize the particle numbers for each spot throughout the target, which can
improve target dose homogeneity when the target lies in heterogeneous tissue or be used
for intensity-modulated particle therapy.
7

1.3

Biological Effects of Ion Beam Radiation

RBE
Although the physical interactions of radiation beams in matter are fairly well understood, the biological effects of radiation are not entirely understood at a mechanistic
level and, generally, are less understood for ion therapy than for photon therapy. However,
what is clearly known is that there can be a different biological effect for the same physical dose given by different types of radiation and different ion species (Hall and Giaccia,
2006). To allow intercomparison of the biological effectiveness of various radiation types,
a common standard has been defined, the relative biological effectiveness (RBE), which is
defined as the ratio of doses between a reference radiation Dreference and a test radiation
Dtest under the condition that both doses produce an identical biological endpoint on the
system studied, expressed as
Dreference
.
(1.3)
RBE =
Dtest
The reference radiation is typically 250 kVp x-rays. Ultimately, the RBE depends on
many factors including the test radiation field and particle type(s), the energy spectrum
of the radiation field, the dose magnitude, the dose rate, the tissue type and cell type, the
exact biological endpoint studied, the oxygenation status of cells, the phase of cells in their
division cycle, the presence or deficiency of DNA damage repair proteins, and a continuing
list of beam specific and subject specific variables. Thus, the most useful RBE values are
those that are experimentally determined under very similar, if not identical, conditions
for a given irradiation where one wishes to know an expected RBE.
RBE versus LET
RBE is known to depend on the linear energy transfer (LET) of charged particles.
LET quantifies the kinetic energy lost by a charged particle traveling through matter per
unit distance. The LET of charged particles is directly related to the inelastic collision
cross section described above and, thus, is also dependent on the charge and velocity of
ions passing through matter. Examples of ion RBE as a function of LET from the literature
are shown in Figure 1.4. For a given ion species, RBE typically increases with LET up
to a certain peak value. The peak RBE versus LET is reached when the average distance
between ionization events roughly coincides with the 2 nm diameter of the DNA double
helix (Hall and Giaccia, 2006). At LET values higher than that of the peak RBE, the
“overkill” phenomena is observed where RBE decreases with further increasing LET. This
8

Figure 1.4: Example of RBE dependence on ion LET and particle species for proton,
helium, and neon irradiation in cell sterilization experiments. Note that RBE generally
increases with LET until reaching a peak RBE, at an LET value depending on the ion
species. After this peak RBE, a further increase in LET leads to a decrease in RBE, i.e.,
the “overkill effect.” Figure reproduced with permission from Schardt et al. (2010). Data
from Scholz (2003).

9

can be understood considering that the absolute number of ions needed to deliver a fixed
macroscopic dose decreases with increasing LET. When the number of ions decreases low
enough, the hitting probability drops significantly. The effectiveness of a single ion track is
very high, but the probability that the ion tracks hit the cell nuclei decreases at very low
particle fluence (Schardt et al., 2010).
The increase of RBE with increasing LET can be better understood by looking at
the distribution of ionization and secondary electrons produced near the projectile track.
Figure 1.5 shows the distribution of secondary electron tracks produced by proton and
carbon ion tracks in water. The high density of secondary electrons near the tracks of
carbon ions leads to the higher RBE seen for carbon. If the ion tracks cross the DNA, the
high density of secondary electrons can cause highly clustered DNA damage that is harder
for the cell to repair than the more diffused damage produced by low LET particles, such
as protons or photons.
An important rationale for choosing an nucleus like carbon, out of all possible elements, is that carbon ions have both a high LET at low energies, such as found near the
Bragg peak, and a low LET at higher energies such as in the beam entrance channel. Therefore, carbon ions used for cancer therapy can provide a favorable combination of high RBE
in diseased tissues near the Bragg peak and a relatively low RBE in normal tissues that
lie upstream of the Bragg peak, e.g., closer to the patient skin surface. This relation was
recently studied in cell survival experiments by Elsässer et al. (2010), shown in Figure 1.6.
Their results suggest that carbon ion therapy might be expected to provide an equivalent
tumor control, with reduced damage to tissues in the beam entrance channel, compared to
proton therapy.
Calculation of Ion Beam RBE for Radiotherapy Planning
For ion radiotherapy, a method to calculate RBE at different locations in the patient
is essential due to the changing energy spectrum of the particle beam with depth in the
patient. The ion therapy project at Lawrence Berkeley Laboratory (LBL) (Berkeley, California, USA) performed extensive cell survival experiments with passively scattered heavy
ion beams using helium, carbon, neon, and argon Lyman and Howard (1977); Chapman
(1977); Chapman et al. (1978). Based on those cell sterilization data, passive scattering
filters were designed to produce a spread-out Bragg peak with decreasing physical dose
near the deeper region of the target which could achieve uniform biological response, i.e.,
cell sterilization, throughout the target. Similar to that approach, the clinical carbon ion
therapy project at National Institute of Radiological Sciences (NIRS) (Chiba, Japan) used
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Figure 1.5.: Microscopic track structure comparing protons and carbon ions at different ener-
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range of secondary electrons roughly coincides with the diameter of the DNA double helix
(see inset diagram), which means that a single traversal of a carbon ion across the DNA
can lead to highly localized, complex damage to the DNA. For an equivalent macroscopic
dose, many more protons are needed than carbon ions, which produces a more diffused
damage to the DNA for protons compared with carbon ions. The diffused damage 17
is easier
for many cells to repair than the clustered damage seen with carbon ions, which explains
the higher RBE of carbon ions compared to protons, especially at low energies (≤ 1 MeV)
found near the Bragg peak. Figure reproduced from Lüchtenborg (2011).

11

Quantification of the relative biological effectiveness d T. ELSÄSSER et al.
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cell survival measurements from human salivary gland tumor cells to design their spreadout Bragg peak for uniform biological effect and established an in-vitro link to their clinical
experience with neutron therapy to prescribe patient doses (Kanai et al., 1997, 1999).
For the clinical carbon ion therapy project at GSI Helmholtzzentrum für Schwerionenforschung (GSI) in Darmstadt, Germany, the “Local Effect Model” (LEM) was developed
to predict ion RBE and enable biological treatment plan optimization for scanned carbon
ion fields with mixed particle types and energy spectra (Scholz et al., 1997; Krämer and
Scholz, 2000; Elsässer et al., 2010). A major premise of the LEM approach is that the
known biological effectiveness of photons can be used to predict the biological effectiveness
of ions on a microscopic dose level. Further, by integrating that microscopic biological
damage pattern predicted for ions over the cell nucleus, one can estimate the macroscopic
RBE, which can be used for treatment planning for cancer therapy.

1.4

Current Challenges for Ion Therapy

Moving Targets
While ion therapy may reduce dose to healthy tissues and thus decrease the potential
for severe side effects of radiation therapy, only a few approaches have been used on patients
with moving thoracic tumors, such as lung cancer patients, who experience the highest
number of deaths each year from cancer in the United States, or Hodgkin lymphoma
patients, who respond well to radiotherapy but are vulnerable to radiation side effects.
Ion beam therapy requires special consideration for moving tumors, compared to photon
therapy, since the motion of heterogeneous tissue can cause large changes in the range of
ion beams.
For passive ion beam delivery, beam-specific margins can be used to encompass target
motion and account for variation in radiological depth of the target (Bush et al., 2004;
Mayahara et al., 2007; Nihei et al., 2005; Slater et al., 1998; Tsuji et al., 2005; Park et
al., 2012). To reduce required motion margins, controlled breathing techniques such as
breath-hold (Hanley et al., 1999; Wong et al., 1997), jet ventilation (Hof et al., 2003), and
even induced apnea (RPTC, 2011), can be used to minimize organ motion. Alternatively,
beam gating systems also allow reduced motion margins and are used clinically with passive
ion beam delivery at several centers (Hashimoto et al., 2006; Iwata et al., 2008; Koto et
al., 2004; Lu et al., 2007; Minohara et al., 2000; Nihei et al., 2006). Bert and Durante
(2011) recently reviewed a number of motion strategies for particle therapy used at several
institutions worldwide, and report that, while passive ion beam therapy is used to treat
13
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Figure 1.7: Sagittal view of scanned carbon ion treatment plans for a lung target (white
contour) with single posterior-to-anterior beam directions (indicated by the black arrows).
Static 3D dose calculation (left) shows highly uniform target dose coverage but ignores
motion. If the same treatment plan is simulated using 4D dose calculation (right), a
severe interplay effect between ion scanning and organ motion is seen, with large regions
of overdose occurring outside of the target region and very low underdosage occurring even
near the center of the target.
patients with moving tumors, scanned ion therapy is not yet used routinely, except for
patients with very small motion.
Given the theoretical dosimetric advantages of using actively scanned ion therapy instead of passively scattered ion therapy, it would appear desirable to use the scanned beam
for thoracic tumors. However, it has been cautioned that scanned ion therapy may not provide reliable dose distributions for cancer sites subject to respiratory motion (Newhauser
et al., 2009), and, indeed, irradiating a moving tumor with a scanned ion beam without
specific countermeasures to address motion has been experimentally shown to cause unacceptable dose coverage of the therapy target, due to interplay between target motion and
delivery of the scanned ion beam (Lambert et al., 2005; Bert et al., 2008). Figure 1.7 shows
3D and 4D dose distributions calculated for scanned carbon ion therapy of a lung cancer
patient and illustrates the dosimetric failure that can occur when no motion mitigation
strategy is used. This calculation demonstrates target underdosage due to interplay near
the very center of the target, which supports that the interplay problem can not be solved
by simple geometric margin expansion of the treatment field.
Motion mitigation studies have been reported that advance the possibility of irradiating a moving tumor with scanned ion therapy (Bert and Durante, 2011). One method,
the use of an internal target volume (ITV) that includes beam-specific range uncertainty
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margins combined with rescanning potentially achieves sufficient target coverage (Phillips
et al., 1992), relying on averaging effects between successive, randomly heterogeneous dose
distributions in the target. However, the motion and range-uncertainty margins required
for the ITV include normal tissue and, therefore, degrade conformity of the dose distribution to the cancer target, potentially reducing one of the main advantages of scanned ion
therapy. Also, the random dose patterns may not always combine to provide uniform dose
with rescanning, which could compromise the tumor control probability. Another method,
gating the irradiation to a small phase window of the respiratory cycle may allow ideal
tumor coverage while maintaining sharp target dose conformity (Minohara et al., 2000).
However, smaller gating windows can lead to longer treatment times and reduce the number of patients that can be treated in a given timeframe. Increasing the gating window,
e.g., from 10% to 30% of the respiratory cycle, reduces the treatment time but potentially
increases required motion margins and increases the chances of interplay effects within the
residual motion window. More elaborate techniques to synchronize the accelerator spill
sequence with the respiratory gating window have been reported and promise to reduce
the treatment time for gating of scanned ion therapy (Tsunashima et al., 2008). Another
method, beam tracking with scanned ion beams is an approach where individual pencil
beams are steered throughout the patient respiratory cycle such that each individual pencil
beam Bragg peak position remains in the same local subvolume of the target for the entire
respiratory cycle (Grözinger et al., 2004; Bert et al., 2007; Saito et al., 2009). This approach
uses magnetic deflection to track lateral target motion and requires a fast, i.e., within several milliseconds, energy modulation system to track changes in radiological depth of the
target. This beam tracking system is further discussed in Chapter 2. One or more of
these motion mitigation strategies might enable the effective use of scanned ion beams for
thoracic cancers in the near future, potentially reducing dose to normal tissue compared
with passively scattered ion therapy. However, the optimal solution to this problem is not
yet known.
Predicting Risks of Radiogenic Second Cancers after Ion Therapy
Along with the technical complexity of delivering scanned ion therapy to moving
thoracic tumors, biological uncertainties make it particularly challenging to estimate risks
of long term side effects of ion therapy, such as radiation-induced malignant neoplasms. This
is particularly important to understand for young patients and those with long expected
survival after radiotherapy. One population that might greatly benefit from scanned ion
therapy is Hodgkin lymphoma patients, who are particularly vulnerable to radiation side
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effects. Lymphomas constitute the highest proportion, that is, nearly 20%, of all incident
primary cancers in adolescents and young adults (Bleyer et al., 2006). Patients diagnosed
with early stage HL and treated with combined chemotherapy and radiation can expect
survival higher than 90% at 5 years (Armitage, 2010) and 60-80% at 20 years, with survival
rates decreasing with age at diagnosis (Bleyer et al., 2006). For this population of patients,
side effects of therapy can in some cases be as devastating as the initial HL diagnosis, e.g.,
second primary cancers, cardiac toxicity, and infertility (Robison et al., 2002). In particular,
radiation therapy can induce malignant neoplasms, i.e., second cancers, presumably by
initiating genomic instability via direct DNA damage or by promoting carcinogenesis via
inflammatory tissue response to radiation (Newhauser and Durante, 2011). In a 25-year
study of 32,591 HL patients with 1,111 25-year survivors, Dores et al. (2002) reported a
10.5% absolute excess risk of cancer in the female breast for patients treated with radiation,
mainly using photon mantle fields. In response to this, research for HL treatment in the
past decades has focused on reducing radiation dose to healthy tissue and the overall size
of therapy fields.
For some HL patients, scanned carbon ion therapy might reduce physical dose to
normal tissues upstream of the target, e.g., breast tissue, compared with scanned proton
therapy, due to the variable RBE and LET discussed above. However, estimation of the
risks of secondary malignant neoplasms for these patients is not straightforward and likely
depends on complex, competing relations between the RBE for HL tumor control, RBE
for normal tissue tumor induction, and RBE for normal tissue sterilization, which likely
all depend on the radiation particle spectrum and the radiosensitivity of individual tissues.
To our knowledge, a study comparing second cancer risk in the breast for HL patients after
carbon ion versus proton radiotherapy has not been reported in the literature.

1.5

Objective of this Study

Objective
The objective of this work was to develop and investigate a new strategy for treating
moving tumors using 4D optimization for scanned ion therapy with beam tracking. We
sought to better understand the robustness of scanned ion beam tracking to motion uncertainties. We also sought to demonstrate that using carbon-ion therapy instead of proton
therapy might offer the ability to reduce risks of secondary malignant neoplasms in healthy
tissue upstream of cancer targets in the thorax.
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Hypothesis
We hypothesized that using 4D-optimized carbon-ion therapy would reduce the predicted risk of radiation induced second cancers in the breast for female Hodgkin lymphoma
patients while preserving tumor control compared with proton therapy.
Specific Aims
1 Determine whether 4D-optimized carbon tracking therapy can reduce dose to volumes outside a moving target while maintaining adequate target dose coverage. We
developed a new scanned ion beam tracking approach using 4D optimization. We
performed water phantom studies and patient studies using computer simulations to
compare dose distributions for moving targets and avoidance volumes for 4D versus
3D-optimized carbon tracking. In addition, we demonstrated the feasibility of our
4D-optimized carbon tracking approach in an experiment using a moving phantom
and a scanned carbon ion beam.
2 Quantify the impact of uncertainties in patient respiratory motion on dose distributions in moving targets for scanned carbon ion beam tracking. We simulated dose
for scanned carbon ion beam tracking using mathematical phantoms and lung cancer
patient 4D computed tomograms (4DCTs). We tested the sensitivity of dose distributions in the target to various systematic and random errors that are characteristic for
lung motion and for the scanned carbon tracking system at GSI. We also investigated
the effects of interfractional changes in organ motion on target dose coverage for the
lung cancer patients by simulating treatment on multi-week 4DCTs.
3 Determine whether using carbon-ion therapy instead of proton therapy reduces the
predicted risk of second cancer incidence in the breast for a sample of Hodgkin lymphoma patients. We simulated scanned proton and scanned carbon ion treatment
for 6 HL patients using a research treatment planning system for ion radiotherapy.
We calculated relative predicted risks of second cancer in the breast using a linearnon-threshold tumor induction model and a linear-quadratic breast cell inactivation
model. In addition, we explicitly modeled RBE for the ion fields for both breast
tumor induction and cell inactivation.
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Rationale
The optimal approach for using scanned ions to treat thoracic targets is not yet
known. We expected that a delivery system that utilized 4D-optimized beam tracking
would provide improved sparing of healthy tissue near a moving target, while achieving
equivalent tumor control, when compared to an existing approach using 3D-optimized beam
tracking. Further, we expected that using carbon-ion therapy instead of proton therapy
would further reduce dose to normal tissue upstream of the target and might reduce the
risk of treatment side effects for patients with thoracic tumors, due to the variable RBE of
carbon beams stopping in tissue.
To test these working hypotheses, we chose to study lung patients as a test case for
4D-optimized beam tracking, since lung tumors can exhibit large motion and dramatic
changes in radiological depth of the tumor, a particularly challenging case for scanned
ion beam tracking. To evaluate the potential of carbon to reduce risks of late effects
compared to protons, we studied HL patients, a test population with a long life expectancy
after therapy and at high risk to develop long term side effects of radiotherapy, including
radiogenic second cancers.
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Chapter 2
4D Optimization for Scanned Ion Beam
Tracking Therapy of Moving Targets
2.1

Introduction

In order to treat patients with moving thoracic tumors using scanned ion beams, motion mitigation strategies are needed to ensure uniform dose coverage of the moving target
and to best minimize dose to normal tissues near the moving target. Beam tracking is one
of the more technically challenging motion mitigation strategies to implement for scanned
ion beams but potentially provides a highly conformal dose to moving targets. In this
approach, individual ion beams are steered throughout the patient respiratory cycle such
that each individual ion-beam Bragg-peak position remains in the same local subvolume
of the target for the entire respiratory cycle. A 4D treatment control system for scanned
ion beam tracking has been implemented for experimental studies at the GSI Helmholtz
Centre for Heavy Ion Research (GSI) in Darmstadt, Germany (cf. Figure 2.1) (Grözinger
et al., 2004). In this system, ion beams can be delivered in any phase of respiration since
the ion beams track all positions of the tumor for the entire respiratory cycle. In addition,
dosimetric target margins for scanned ion beam tracking theoretically remain as sharp and
conformal as that possible for a non-moving cancer site.
For treatment planning of scanned ion beam tracking (Bert and Rietzel, 2007), particle
numbers for each pencil beam are first optimized to provide target dose coverage for a single
respiratory motion state, e.g., at end-exhale, and, then, required tracking offsets for each
pencil beam are computed for all other motion states of respiration. Tracking offsets are
calculated using both 4DCT image data and deformable image registration vectors, which
register anatomic motion through the discrete temporal states of respiration, represented
by the 4DCT. Lateral-tracking offsets are calculated by projecting the deformable image
registration vectors onto a plane perpendicular to the beam axis. Range-tracking offsets
19
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Figure 2.1: Beam tracking system for scanned ion therapy implemented at GSI. The ion
beam is produced by linear and synchrotron acceleration and extracted by a radiofrequency
(RF) knockout exciter. Dipole scanner magnets steer the ion pencil beams laterally to
achieve target coverage and to track target motion. A system of acrylic wedges mounted
on linear drive motors modifies the range of individual pencil beams to track changes in
radiological depth of the target (Saito et al., 2009). A motion monitoring system provides
feedback to the 4D therapy control system, which transmits precomputed beam tracking
offsets for each pencil beam and each motion state to the scanner magnets and wedge
system, so that each pencil beam follows the target motion.
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require a more complex calculation using both the deformable image registration vectors
and a recalculation of the radiological depth of the target for each motion state. This beam
tracking approach of Bert and Rietzel (2007) can achieve adequate target dose coverage
for some patients but does not provide a solution for patients with tumors that deform or
rotate significantly during respiration. To address this problem, Lüchtenborg et al. (2011)
recently developed a real-time dose compensation method for beam tracking that improves
target dose coverage for scanned ion beam tracking by adapting particle numbers in realtime based on the motion status of the target during the delivery of each pencil beam. We
wish to emphasize that each of these beam-tracking approaches are novel and have not yet
been applied to patient treatment. The ideal method to apply scanned ion beam tracking
therapy to patients is not yet known. Based on the approach of Lüchtenborg et al. (2011),
we were inspired to investigate 4D optimization as a strategy to further improve target
dose coverage and potentially control dose to healthy tissue for scanned ion beam tracking.
Whereas many motion mitigation strategies attempt to eliminate or reduce the impact of
time and motion as factors in therapy, we sought to exploit time and motion as potential
advantages in therapy using 4D optimization.
Several studies have reported 4D optimization strategies for photon therapy. Zhang et
al. (2004) incorporated respiratory motion data into optimization of photon tomotherapy
plans and demonstrated improved target dose conformity. Trofimov et al. (2005) developed four new approaches to optimize intensity-modulated photon fields for lung and liver
patients with moving tumors. Nohadani et al. (2010) reported another 4D optimization
approach for photon therapy that improved dose coverage compared to beam gating for
lung cancer patients and reduced dose to healthy lung and was also more robust to irregular breathing than beam gating. Chin and Otto (2011) further demonstrated in phantom
studies that 4D optimization can be applied to volumetric modulated arc therapy to spare
avoidance volumes near a moving target. These studies suggest that the added degree of
freedom, i.e., time, in optimization can be used to improve target dose coverage and to spare
avoidance volumes near a moving target. However, to our knowledge, 4D optimization for
ion therapy has not been previously reported in the literature.
The purpose of our study was to develop and test a new beam tracking approach using
4D optimization for scanned ion therapy of moving tumors. We tested the working hypothesis that 4D-optimized scanned ion beam tracking can reduce dose to avoidance volumes
outside a moving target compared with 3D-optimized scanned carbon beam tracking while
maintaining adequate target dose coverage. The following section begins with a description
of our implementation of a 4D-optimization algorithm in a treatment planning system for
scanned ion therapy. Then, we describe two treatment-planning studies, one for a water
21

phantom and another for a lung cancer patient, in which we compared our 4D-optimized
beam-tracking approach against an existing 3D-optimized beam-tracking approach. Finally,
we discuss a simple experiment using moving films and a scanned carbon ion beam-tracking
system that provides preliminary evidence that our approach is technically feasible.

2.2

Methods

2.2.1

4D Optimization

In this work, we designed a 4D-optimization approach for scanned ion beam tracking
therapy. Our approach involves planning of a 4D field composed of ion pencil beams, each
with a unique geometric position, energy, and particle number (i.e., number of particles
incident on the patient in that pencil beam), determined for individual motion states. To
illustrate our theoretical concept, a diagram comparing 4D-optimized scanned ion beam
tracking versus an existing 3D-optimized scanned ion beam tracking method is shown in
Figure 2.2. By optimizing the particle numbers for each pencil beam for each motion state,
we sought to calculate 4D fields that could accumulate a uniform dose to a moving target,
but, possibly, reduce dose to avoidance volumes near the moving target, compared with a
3D-optimized beam tracking approach.
We implemented our approach in the TRiP4D research treatment planning system
(TPS) code for scanned ion therapy (Krämer et al., 2000; Bert and Rietzel, 2007; Richter
et al., 2013) using the C programming language. We used much of the existing TPS code,
which could already calculate 4D dose distributions and plan beam-tracking offsets. In
addition, we substantially extended the optimization routines to incorporate 4DCT data,
deformable image registration vectors, and beam tracking offsets that were necessary to
enable optimization of a 4D field.
Our treatment planning workflow for 4D-optimized scanned ion beam tracking included a sequence of the following steps.
1 A 3D scanned ion field was planned to cover a 3D representation of the 4D clinical
target volume (CTV) in a reference motion state, with Bragg peaks for each pencil
beam evenly spaced throughout the target volume. This step required a 3D computed
tomogram (CT) extracted from a 4DCT, i.e., representing the patient in the reference
state, and CTV contours to determine the necessary energies and lateral coordinates
of ion pencil beams.
2 Particle numbers were optimized for the 3D scanned ion field to provide uniform dose
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Figure 2.2: Schematic drawing comparing 4D- versus 3D-optimized scanned ion beam
tracking in beams eye view. A circular target (black) moves between three motion states.
For 3D-optimized tracking (a, b, and c) pencil beams (smaller blue circles) track the target
motion and deliver identical particle fluence for each motion state. For 4D-optimized
tracking, fluence is reduced for Motion State 2 (e) when the target is closest to the organ at
risk (green). To compensate, fluence must be increased for pencil beams in Motion States
1 and 3 when the target is furthest from the organ at risk (d and f). Relative fluence is
indicated by the shade of blue for each pencil beam.
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throughout the CTV for the reference motion state.
3 To plan beam tracking, deformable image registration vectors and 4DCTs were used
to calculate beam tracking offsets for each pencil beam for each motion state, so
that each pencil beam would track changes in target position and radiological depth
during treatment. Thus, the treatment plan at this stage was composed of a 3D field
and a 4D look-up table of tracking offsets (Bert and Rietzel, 2007).
4 As the starting condition for the 4D field, the 3D field, created in Steps 1 and 2, was
copied for each of M motion states, corresponding to states of the 4DCT, to produce
a 4D field. Tracking offsets for each pencil beam for each motion state were included
in the 4D field description. Initially, particle numbers for each pencil beam in all
motion states of the 4D field were identical to those in the 3D field, though scaled
uniformly by 1/M .
5 For 4D optimization of the particle numbers N in the 4D fields, a dose correlation
matrix A was calculated that contained the dose contribution, per incident particle
number (nijk ), for each ion pencil beam (i) in each motion state (j) for each field
(k) to each voxel (p) in the target and avoidance volumes. To calculate the dose
correlation matrix elements (aijkp ) of A, 4D pencil beam dose calculations were performed similarly to 3D pencil beam dose calculations except that (1) individual voxel
coordinates, defined in a reference motion state, for the target and avoidance volumes
were transformed for non-reference motion states using deformable image registration
vectors, (2) individual ion pencil beams were offset by their tracking offsets that were
determined in Step 3, and (3) the appropriate 3DCT state from the 4DCT was used
in dose calculation. The resulting dose correlation matrix was used to calculate 4D
dose to the pth (moving) voxel by

Dp (N) =

Ljk
B X
M X
X

aijkp nijk

(2.1)

k=1 j=1 i=1

where Ljk is the number of pencil beams in an individual motion state j for a given
field k. B is the number of fields used, e.g., with different gantry angle or couch
angle. In this study, we only used single fields (B = 1), but our TPS developments
can be used for multi-field intensity-modulated optimization.
6 An objective function χ2 (N) was defined to express differences between the prescribed
and actual dose to the target (T ) and to penalize dose to avoidance volumes (V ) above
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a given threshold dose for each avoidance volume (Horcicka, 2011).
χ2 (N) =

X

wT (DRx − Dp (N))2 +

p∈T

X

wV (DMax − Dp (N))2 Θ (Dp (N) − DMax )

p∈V

(2.2)
where DRx was the prescribed target dose and the terms wT and wV were adjustable
parameters to weight the objective function to greater emphasize either prescribed
target dose coverage or avoidance volume dose exceeding a maximum allowed value
DMax , as desired. The Heaviside step function Θ served to exclude voxels receiving
a dose below a user specified maximum dose limit DMax from adding penalty to the
objective function. Specifying DMax for avoidance volumes near the target allowed
fine control over tradeoffs between the competing objectives of uniform target dose
coverage and minimal dose to avoidance volumes.
7 Conjugate gradients minimization with the Fletcher-Reeves extension (Press et al.,
2007) was used to solve for particle numbers N in the 4D scanned ion field that
minimized the objective function.
After optimizing the 4D fields, we were able to compute 4D dose distributions using
the existing functionality of TRiP4D (Richter et al., 2013). It should be noted that, in this
chapter, we only worked with absorbed dose and further development of TRiP4D is needed
to allow 4D-optimization of RBE-weighted dose. The treatment planning steps described
above were used in the following studies for both a moving phantom and a lung cancer
patient to test our working hypothesis.
2.2.2

Water Phantom Study

To compare our 4D-optimized scanned ion beam tracking approach against an existing
3D-optimized scanned ion beam tracking approach, we designed a water phantom test
case with a moving spherical target deep to a static rectangular solid avoidance volume
(cf. Figure 2.3). The mathematical phantom consisted of two rectangular solid slabs. A
proximal slab 10 × 10 × 2 cm3 contained a stationary rectangular solid avoidance volume
2 × 10 × 2 cm3 , upstream of the target, and did not move. A distal slab 10 × 10 × 8 cm3
contained a 3-cm spherical target volume and oscillated along the x-axis, perpendicular to
the beam direction, with sinusoidal motion with 2-cm peak-to-peak amplitude and a 4 s
period. We designed this phantom to allow two distant motion states in which beams could
deliver dose to portions of the target and while missing the avoidance volume.
For treatment planning simulations, voxelized 4DCT data and contours were gener25
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Figure 2.3: Diagram of water phantom test case from 2 viewpoints. A spherical target
(black circle) with 3-cm diameter moves laterally along the x-axis with sinusoidal motion
(Ax = 2 cm, T = 4 s) deep to a static proximal avoidance volume (grey shaded rectangle).
Beam direction indicated by black arrow. The target is shown by the solid circle in the
reference motion state and by the dashed circle at maximal displacement.
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ated to represent this phantom, and corresponding image registration vectors were created
to describe the sinusoidal motion of the phantom for 11 discrete motion states equally
spaced, i.e., in distance, between the minimal and maximal displacement of the moving
phantom. Using the TPS, a single scanned carbon ion field was designed to irradiate the
spherical target uniformly with 1 Gy, with the beam first passing through the stationary
slab containing the avoidance volume. Carbon pencil beam Bragg peak positions were
distributed throughout the target with 2 mm lateral spacing and 3 mm water-equivalent
depth spacing and focused to approximately 6 mm full-width at half-maximum (FWHM)
spot size each, i.e., at the center of the target. A 3-mm ripple filter was used to broaden
the width of the carbon Bragg peaks along the depth axis.
The 3D-optimized beam tracking plan was prepared using only steps 1-3 in our described procedure in Section 2.2.1 and was composed of a 3D field and a list of tracking
offsets for each pencil beam for each motion state. We did not restrict dose to the avoidance
volume in 3D optimization for this water phantom case. For 3D optimization, our solution
was considered to have converged and optimization was stopped on once the relative change
in our objective function after each iteration dropped below 1 × 10−3 . The 4D-optimized
scanned carbon tracking plan was prepared as described in Steps 1-7. For 4D optimization
objectives, we included a uniform target dose of 1 Gy (wT = 1) and a maximum dose to
the avoidance volume of 0.01 Gy (wV = 0.01). To prevent the occurrence of overly high
doses in regions outside the target and avoidance volume, we also added a thin avoidance
volume layer, 2-mm depth-thickness at 2-cm depth, throughout the entire proximal slab,
with a maximum allowed dose of 1 Gy (wV = 1).
We investigated the rate of convergence of the 4D objective function as a function of
the number of iterations. Based on our initial findings, we decided not to use the stopping
criteria discussed above but, rather, to continue until 1000 iterations were completed. We
will return to this topic in our discussion. 4D dose calculations were performed for both
3D- and 4D-optimized scanned carbon beam tracking for the moving phantom. A 3D dose
calculation was also performed for a static reference case without motion.
In summary, our water phantom study compared calculated dose to the target and
avoidance volume for (1) static 3D irradiation with the target fixed in the reference motion
state, (2) 3D-optimized scanned carbon beam tracking, and (3) 4D-optimized scanned
carbon beam tracking. 4D dose distributions were transformed to the reference motion
state and visualized using 2D colorwash plots of dose.
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2.2.3

Lung Cancer Patient Study

In order to demonstrate that our 4D-optimized beam tracking approach could optimize 4D scanned carbon fields for patients with moving organs, we tested our method for
a lung cancer patient, who we will refer to as Lung Patient #1 throughout this work. The
59-year-old woman in our study was diagnosed with stage IV, T2/N2/M1, non-small-cell
lung cancer and a 4.5-cm primary tumor in the left lower lobe near the heart. She received
stereotactic x-ray radiosurgery at The University of Texas M. D. Anderson Cancer Center
(UTMDACC) (Houston, TX). Prior to her treatment, 4DCT image data were acquired with
a 16-slice CT scanner (Philips, Mx8000 IDT, Amsterdam, The Netherlands) and binned
into 10 phases of the respiratory cycle with equal duration (Keall et al., 2004). Data for this
patient were collected under a retrospective research protocol approved by the UTMDACC
Institutional Review Board. All protected health information was removed from our copy
of the electronic medical record.
In order to plan beam tracking and to perform 4D dose calculations, deformable
4D image registration vectors were calculated from the 4DCT data using the Plastimatch
software system (Shackleford et al., 2010). Deformable image registration vectors are shown
over a CT slice for the reference phase at end-exhale in Figure 2.4 to illustrate the extent
of organ motion in this patient case.
Using the TPS, we designed a single posterior-to-anterior scanned ion field to irradiate
the CTV. Although a lone field would most likely not be used clinically, we chose this to
evaluate performance of our algorithm at the distal target edge near the heart. For a
reference motion state at end-exhale, positions of the carbon pencil beam Bragg peaks
were planned to cover the CTV with a uniform 2-mm lateral spacing and focal size of
6-mm FWHM. We used a 3-mm water-equivalent spacing between isoenergy slices and a
corresponding 3 mm ripple filter. Particle numbers for each pencil beam were initially
optimized in 3D to provide 100% of the prescribed dose to the CTV (wT = 1.0) and zero
dose to the heart (wV = 10.0). 3D optimization was stopped once the relative change in
the objective function dropped below 1 × 10−3 between each iteration. Where the CTV
contours overlapped the heart volume, that volume was treated as target. After planning
a 3D field to irradiate the target in the reference motion state, beam tracking offsets were
computed for each pencil beam in each motion state using 4D deformable image registration
vectors and 4DCT data, as described in steps 1-3 in Section 2.1. For 4D-optimized beam
tracking, we performed steps 1-7 in Section 2.1. For 4D optimization, we specified criteria
of uniform CTV dose coverage (wT = 1.0) and a limit of zero dose to the heart (wV = 10.0).
As in the water phantom study, we investigated convergence of the 4D objective function
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Figure 2.4: Sagittal CT slice for the lung cancer patient in the reference motion state
at end-exhale. The CTV is indicated by the orange contour, and the heart contour is
shown in white. The overlaid red vectors indicate the YZ components of the deformable
image registration vectors and show the movement of tissue to a different motion state at
full-inhale.
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as a function of the number of iterations. Based on this, we used 1000 iterations with no
stopping criteria.
We computed 4D dose distributions in the lung patient for static irradiation, 3Doptimized beam tracking, and 4D-optimized beam tracking. All 4D dose distributions
were transformed to a 3D reference state at end-exhale for analysis. Dose distributions
were compared using 2D dose colorwash planes, dose volume histograms, and dose-volume
statistics.
2.2.4

Validation Experiment

To demonstrate feasibility of delivering 4D-optimized beam tracking therapy, we performed an experiment using the GSI synchrotron with a carbon beam, a motion phantom,
and radiographic films. Similar to the mathematical phantom described in Section 2.2.2,
a disk-shaped moving target was defined with 3-cm diameter and sinusoidal motion with
2-cm amplitude and 4-s period perpendicular to the beam central axis. We planned a single
isoenergy layer of carbon ion pencil beams with 2-mm spacing to deliver uniform dose to
the moving target and minimal dose to the static avoidance volume upstream of the target.
Experimentally, this case was represented by 1 radiographic film (Eastman Kodak,
X-OMAT V, Rochester, USA) placed, in its jacket, on a motorized table at isocenter
on the patient couch and 1 film placed upstream of the motorized table, which did not
move. A laser distance indicator was used to detect target motion for our 4D treatment
control system. Our experimental setup is shown in Figure 2.5. We delivered our 4D
scanned carbon fields to the films using a sequential gating technique. For example, all
particles prescribed for motion state 1 were delivered before any particles were delivered
for motion state 2. In the case that a motion state change occurred before irradiation
was finished, the particle spill was gated by stopping the radiofrequency knockout exciter
until the motion table returned to the unfinished motion state and the spill extraction was
resumed. In this manner, we irradiated scanned carbon ion treatment plans using both
3D-optimized beam tracking and 4D-optimized beam tracking. Films were processed and
digitally scanned using standard methods, and we analyzed the film exposure, i.e., optical
density, in both the moving target region and the avoidance region of the films for both
3D- and 4D-optimized beam tracking.
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Figure 2.5: Experimental setup for the 4D-optimized beam tracking experiment. The
phantom consisted of 2 acrylic pieces (built at the GSI machine shop), which were designed
to house an array of ionization chambers and radiographic films. The first phantom piece
was positioned stationary upstream of the target. The second moving target phantom piece
was mounted on a motion table designed for sinusoidal 1D motion with 2-cm amplitude,
driven by an electric DC motor. A laser distance indicator monitored the position of
the motion table and transmitted a signal to the 4D treatment control system, which
determined the motion state of the phantom for 4D treatment delivery. Although we
designed our phantom to hold ionization chambers (shown), these were not installed during
our experiment due to severe time constraints.
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Figure 2.6: Beams eye views of carbon ion scan patterns, i.e., fluence maps, for a single
energy (201.65 MeV/u) comparing 3D-optimized beam tracking (a, b, c) and 4D-optimized
beam tracking (d, e, f). The ion scan path (thin pink line), stationary avoidance volume
(blue rectangle) and moving target (red circle) are shown for exemplary motion states 0
(a, d), 5 (b, e), and 10 (c, f). Relative particle numbers for each pencil beam are indicated
by the size of the black squares.

2.3

Results

Overall, we observed that 4D optimization performed as expected. The added degrees
of freedom attained by adjusting particle numbers for each pencil beam for each motion
state allowed advantages such as reduced dose to avoidance volumes and improved target
dose uniformity.
2.3.1

Water Phantom Study

Carbon ion particle numbers N were determined for 3D- and 4D-optimized beam
tracking. Fluence maps for a single energy-slice are shown in Figure 2.6. As expected,
particle numbers were reduced by 4D optimization for certain motion states for pencil beams
that passed through the static avoidance volume to reach the deeper target. To compensate
this, particle numbers were increased using 4D optimization for those motion states that
allowed pencil beams to irradiate the target without passing through the proximal avoidance
volume.
In 4D optimization, the evaluation of the objective function χ2 (N) is shown as a
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function of iteration number in Figure 2.7. To better visualize dosimetric improvements
as a function of iteration number, 4D dose distributions are plotted for various iteration
numbers in Figure 2.8. Due to our choice of optimization constraints, the target dose was
drastically decreased in the first iteration to spare dose to the avoidance volume. However,
after a large number of iterations the target dose coverage was restored, even though a
reduction of dose to the avoidance volume was maintained.
Figure 2.9 plots 2D dose colorwash planes comparing 4D-optimized beam tracking
against 3D-optimized beam tracking, along with a static irradiation. Dose to the avoidance
volume for 4D-optimized beam tracking was greatly reduced, mean dose decreased by 70%
and maximal dose decreased by 53%, compared to 3D-optimized plans. Dose statistics for
the moving sphere and avoidance volume are presented in Table 2.1 for each treatment
plan. For all treatment plans, dose coverage to the moving target was nearly identical. For
the avoidance volume, dose distributions for the 3D-optimized beam tracking plan and the
static irradiation plan were similar, though the dose distribution for 3D-optimized tracking
appeared generally blurred along the x-axis in the proximal, stationary slab containing the
avoidance volume, as expected because the carbon pencil beams were laterally tracking the
deeper moving target during irradiation.
2.3.2

Lung Cancer Patient Study

For the lung cancer patient, we observed a lesser ability to minimize dose to the
avoidance volume, i.e., the heart, than observed for our water phantom study, using 4Doptimized beam tracking instead of 3D-optimized beam tracking. However, we achieved a
highly uniform target dose using 4D optimization, similar to that for a static irradiation.
Dose colorwash planes comparing 4D-optimized tracking against 3D-optimized tracking
and static irradiation are shown in Figure 2.10 for the lung cancer patient. The same data
are shown in DVH form in Figure 2.11. In addition, the evaluation of the objective function
χ2 (N) is shown as a function of iteration number in Figure 2.12 for the lung patient. For
the static irradiation, the target dose distribution appeared uniform throughout the CTV.
3D-optimized beam tracking provided a dose distribution that remained conformal to the
geometric target boundary. However, degradation of dose uniformity was observed inside
the target with regions of overdose and underdose. In particular, a region of overdose
extends distally beyond the CTV into the heart. This non-ideal dose coverage likely results
because 3D-optimized tracking does not compensate for dosimetric effects of rotating or
deforming tissues or for changes in the scattering properties of material upstream of the
target. We describe these issues in further detail in the discussion section. In summary,
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Figure 2.7: Objective function (top) and relative change in objective function (bottom)
versus number of iterations for 4D-optimized beam tracking for the water phantom. The
erratic shape of the relative change in objective function in early iterations led us to abandon
our typical criteria for terminating optimization, i.e., to stop when the relative change
dropped below 1 × 10−3 . Instead, we estimated from these plots that the relative change in
the objective function become stable and remains below 1×10−3 near 1000 iterations. Thus
we used 1000 iterations of 4D optimization without any abort criteria for the rest of our
study, and we visually confirmed that the objective function did not worsen by neglecting
the typical stopping criteria.
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Figure 2.8: Target and avoidance volume dose statistics versus number of iterations for
4D-optimized beam tracking for the water phantom. Target mean (D̄), standard deviation
(error bars), minimum (Dmin ), and maximum dose (Dmax ) are shown by the black markers
connected by solid lines. Avoidance volume mean and maximum dose are shown by the red
markers connected by dashed lines. During the first 10 iterations, dose is increased both to
the target and the avoidance volume. After the target dose stabilizes near iteration 1000, a
continued reduction in maximum dose to the avoidance volume is seen even up to 100,000
iterations, inspiring us to investigate other minimization algorithms in future studies.
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Figure 2.9: XZ dose colorplanes for the moving sphere target in a water phantom with
a static proximal avoidance volume. 4D dose distributions were calculated for (a) 3Doptimized carbon static plan for a non-moving target in the reference motion state, (b)
3D-optimized carbon beam tracking plan for a moving target, and (c) 4D-optimized carbon
beam tracking plan for a moving target. Sphere target shown in the reference position (solid
circle) and at maximal displacement (dashed circle). The proximal avoidance structure
(solid square) and water above Z = 80 mm (dashed line) did not move. Illustrations of
carbon pencil beam fluence for each case are shown above the phantoms to demonstrate:
(a) pencil beams do not move, (b) pencil beams track the lateral motion of the sphere
target, but fluence for each pencil beam is identical to the static 3D plan, and (c) pencil
beams track the lateral motion of the target with pencil beam fluence optimized for each
motion state to best spare the avoidance structure and maintain target coverage.
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Table 2.1: Dose and volume statistics comparing 3D optimized static delivery, 3D optimized
beam tracking, and 4D optimized beam tracking for both the water phantom and lung
cancer patient studies. Data reported as percentages. Difference calculated as 100% ×
(4DOBT − 3DOBT)/3DOBT.
Study

Volume

Phantom

Target

Patient

Static

3DOBT

4DOBT

Difference (%)

D̄
σD
Dmin
Dmax
V95
V107
D5 − D95
Avoidance D̄
Dmax

100.0
0.3
98.3
101.2
100.0
0.0
1.8
23.8
91.5

100.0
0.3
98.3
101.2
100.0
0.0
1.8
26.1
89.4

99.9
0.4
97.3
101.5
100.0
0.0
1.9
7.7
42.2

0
+58
-1
0
0
0
+1
-71
-53

CTV

99.9
1.9
34.2
114.5
99.7
0.2
2.0
7.0
104.7

95.4
12.0
37.9
126.7
50.4
19.5
38.7
6.9
119.4

100.0
0.9
54.7
108.9
99.9
0.1
1.9
7.1
103.8

+5
-93
+44
-14
+98
-100
-95
+3
-13

Heart

Metric

D̄
σD
Dmin
Dmax
V95
V107
D5 − D95
D̄
Dmax
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Dose

Figure 2.10: Sagittal cuts showing (a) CT image of lower thorax, (b) 3D dose for the
3D-optimized carbon static plan ignoring motion, (c) 4D dose for the 3D-optimized beam
tracking plan, (d) 4D dose for the 4D-optimized carbon beam tracking plan. All 4D dose
distributions were transformed to the reference motion state at end-exhale for analysis.
Note the increased uniformity of CTV dose using 4D-optimized beam tracking (d) instead
of 3D-optimized beam tracking (c).
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Figure 2.11: 4D cumulative DVHs for the lung CTV and the heart shown in linear (top)
and semilog (bottom) scales comparing (1) 3D-optimized static plan (dashed red line),
(2) 3D-optimized beam tracking (dotted blue line), and (3) 4D-optimized beam tracking
(solid black line). 4D-optimized beam tracking appears similar to the static plan with more
uniform target dose coverage and slightly reduced maximal dose to the heart, compared
with 3D-optimized beam tracking.
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Figure 2.12: Objective function (top) and relative change in objective function (bottom)versus number of iterations for 4D-optimized beam tracking for the lung patient.
Similar to the water phantom results (cf. Figure 2.7), we observed from these plots that
the relative change in the objective function is somewhat erratic but seems to fall consistently below 1 × 10−3 near 1000 iterations.
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4D-optimized beam tracking improved target dose uniformity, compared to 3D-optimized
beam tracking. In addition, by using 4D-optimized tracking we observed a 13% decrease in
maximum dose to the heart, compared to 3D-optimized tracking (cf. Table 2.1). Analysis
of the organ motion seen in the deformable image registration map (cf. Figure 2.4) suggests
that similar motion between the lung CTV and the heart restricted our ability to reduce
dose to the heart as greatly as that possible in our water phantom study.
2.3.3

Validation Experiment

We experimentally confirmed the ability of 4D-optimized beam tracking to reduce dose
to an avoidance volume near a moving target compared with 3D-optimized beam tracking
for our moving target phantom using a scanned carbon ion beam at GSI. Figure 2.13 shows
our film measurements from the 4D-optimized beam tracking validation experiment. We
observed that 4D-optimized beam tracking provided a similar uniformity of film darkening
to 3D-optimized beam tracking for the moving target, with mean optical densities of film
in the target region of 1.00 ± 0.14 and 1.00 ± 0.10, respectively. However, 4D-optimized
beam tracking provided much less dose to the avoidance region than 3D-optimized beam
tracking, as seen in the lighter film exposure in that region, with mean optical densities
in the avoidance region of 0.26 and 0.71, respectively, and max optical densities in the
avoidance region of 0.79 and 1.37, respectively. Thus, using 4D-optimized beam tracking
instead of 3D-optimized beam tracking reduced the mean film exposure in the avoidance
region by 63% and reduced the max film exposure in the avoidance region by 42%. These
measurements support our findings in-silico and provide evidence that our 4D-optimized
beam tracking approach is technically feasible to deliver using a carbon ion synchrotron.

2.4

Discussion

In conclusion, we confirmed our hypothesis that 4D-optimized scanned ion beam
tracking can reduce the maximum dose to avoidance volumes near a moving target compared with 3D-optimized scanned ion beam tracking. In addition, 4D-optimized beam
tracking substantially improved target dose homogeneity for a lung tumor, compared with
3D-optimized beam tracking.
In our water phantom study, we demonstrated that a drastic reduction in dose to
avoidance volumes near a moving target is possible using 4D-optimized beam tracking
instead of 3D-optimized beam tracking. The clinical significance of this finding will likely
depend greatly on the exact motion characteristics of the target and avoidance tissues for
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Figure 2.13: Experimental film results for scanned carbon ion delivery of 4D-optimized
beam tracking (right) versus 3D-optimized beam tracking (left) using the GSI synchrotron
facility. We found that 4D-optimized beam tracking drastically reduced dose to the static
avoidance volume (red rectangle), as seen by less film darkening compared to 3D-optimized
beam tracking, while both approaches produced similar uniform darkening of the moving
circular target.
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individual patients. In our lung cancer patient study, we observed a less dramatic sparing
of dose to the heart using 4D optimization. The less dramatic sparing of the avoidance
volume seen in the patient compared with the water phantom is likely a consequence of the
nearly identical motion between the target and the avoidance volume, i.e., the heart.
Thus, it appears that differential motion between target and avoidance volumes is
a likely prerequisite to achieve clinically significant reductions in dose to avoidance volumes using 4D-optimized scanned ion beam tracking. Therefore, more patient studies are
required to isolate patient populations that would benefit most from this therapy. Of
perhaps equal importance, we found that 4D-optimized beam tracking could drastically
improve target dose coverage and dose uniformity for the lung cancer patient. This finding potentially benefits a large class of patients with targets that undergo periodic motion
during treatment. Also, 3D-optimized beam tracking seems to pose a risk for degraded
uniformity of tumor dose, compared to both 4D-optimized beam tracking and static dose
simulations. This cautions that using beam tracking for deforming tissue without using 4D
optimization or other correction methods (e.g., those of Lüchtenborg et al. (2011)) may
provide dosimetrically worse coverage than beam gating.
For 3D-optimized beam tracking for the lung patient, this finding of non-uniform
target dose for “perfect” tracking agrees with previous studies of Bert and Rietzel (2007)
and van de Water et al. (2009) who reported that dose degradation can result from issues
that are not considered in 3D-optimized beam tracking, namely rotations, deformations,
and changes in scattering properties of tissue upstream to the target. For example, if the
target rotates, the entrance channel dose for individual pencil beams can overlap in irregular
patterns. If the target deforms, the geometric spacing between pencil beams may change,
and due to the high dose gradients for each pencil beam, one may observe overdose when
volume contraction occurs and underdose when volume dilation occurs. Further, if the
target moves, even rigidly, beneath heterogeneous tissue upstream of the target, e.g., lung
tumor moving beneath ribs, the multiple Coulomb scattering of individual pencil beams,
and thus distribution of off-axis target dose contributions, will not be uniform for all motion
states even if the range variations are compensated by beam tracking. Some of these issues
were recently addressed by the study of Lüchtenborg et al. (2011), who developed a realtime 4D dose correction method that achieved improved target dose coverage compared
with 3D-optimized beam tracking. The advantage of their method compared to ours might
be faster patient throughput, since their technique allows irradiation of the patient during
any given motion state. In contrast, our approach solves a 4D field that potentially better
spares avoidance volumes and might offer slightly more uniform target dose but must be
delivered during specific motion states, similar to gating.
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In comparison to published literature on 4D-optimization for photon therapy, our
approach was similar to that of Trofimov et al. (2005), using a deforming dose calculation
grid and discrete motion states, though scanned ion beam therapy includes an additional
degree of freedom compared to photon therapy, due to the multiple isoenergy layers. Our
findings for the lung patient are consistent with those of Trofimov et al. (2005), who found
only slight reductions of dose to avoidance volumes for lung and liver patients using 4Doptimized photon beam tracking instead of photon beam gating. Similar to Chin and
Otto (2011), we observed large ability to spare avoidance volumes near moving target for
phantom cases.
Our study had several notable strengths. To our knowledge, this is the first study of
4D optimization for scanned ion beam therapy of moving tumors reported in the literature.
We achieved improved target dose coverage and reduced dose to avoidance volumes by
incorporating the entire 4DCT data set into 4D optimization of the scanned ion fields. Since
we use the 4DCT and deformable image registration vectors in optimization, our approach
provided a more uniform target dose than 3D-optimized beam tracking for a moving target
in heterogeneous tissue. In addition, we validated our work with an experiment using a
scanned carbon ion beam and a moving phantom.
Our study had several limitations. One was that we did not consider uncertainties
in patient motion, and we assumed that the exact characteristics of patient anatomy and
motion could be represented by a single planning 4DCT. Though our approach allows variation in respiratory rate, we ultimately assumed that motion was periodic. Any substantial
deviations from that assumption could result in treatment failure. However, this limitation
was not important in the context of this study because we only sought to demonstrate
proof-of-principle that 4D optimization could potentially provide a benefit for scanned ion
therapy for moving organs. A second limitation was that we only considered absorbed dose
from scanned carbon ion therapy, i.e., our modifications of the TRiP4D research code to allow simulation of 4D-optimized beam tracking did not allow optimization of RBE-weighted
dose for our lung patient. Further work is needed to connect our approach with a method
to optimize RBE-weighted dose, e.g., the Local Effect Model used at GSI. Third, in this
work, we encountered computer memory limitations during 4D optimization due to the
large problem size when using our current 32-bit treatment planning system. Therefore,
we downsampled the 4DCT images from original voxel sizes of (0.98 x 0.98 x 2.5) mm3
to voxel sizes of (2.93 x 2.93 x 2.5) mm3 . This limitation is currently being addressed
by extension of TRiP4D to utilize 64-bit computer architecture. A fourth limitation was
that we only investigated one minimization algorithm, i.e., conjugate gradients, which may
converge on local minima rather than a global minimum. Fifth, we only investigated one
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beam angle for each test case. However, our codes can be used to optimize multiple beams
simultaneously to plan 4D-optimized intensity modulated particle therapy. Some of these
limitations were intended by the design of our study and allowed us to see things that could
have otherwise been confounded by increasing the complexity of our study. While we acknowledge these limitations of our work, they did not prevent us from achieving our goals,
which were to demonstrate proof-of-concept for a new beam tracking approach using 4D
optimization and to investigate possible dose reductions for avoidance volumes near moving
targets. In addition, some of these limitations are addressed in the following chapter.
4D optimization for scanned ion therapy has many possible avenues for future work.
For example, 4D optimization might be used to simplify the beam tracking system at
GSI. By using an appropriate starting condition, such as a 4D scanned ion field with a
pencil beam grid covering the full range of target motion and range changes, one might
eliminate the need for tracking offsets and, rather, achieve tracking solely by optimizing
the particle numbers for pencil beams in the rigid grid for each motion state. For patients
with slightly irregular motion trajectories, it should be theoretically possible to incorporate
several 4DCT series into the optimization of a single beam tracking plan that is more robust
to each possible trajectory represented by the individual 4DCTs. For chaotic motion, such
as seen in the abdomen near the bowel, the 4D optimization concept could potentially be
modified to provide a robust 3D field solution that is optimized using multiple 3DCT image
sets acquired, e.g., on different days prior to treatment.
In summary, we developed and tested a 4D-optimized beam tracking approach for
scanned ion therapy that provided reduced dose to avoidance volumes and improved target dose coverage for a patient with a moving target, compared with 3D-optimized beam
tracking. Theoretically, these dosimetric advantages can be used either to provide reduced
risk of treatment side effects when target doses are designed for a standard tumor control
probability or can allow increased target doses and improved tumor control probability
when risks of treatment side effects are allowed to approach those risk levels typical of
standard care. Either avenue may be valuable to improving patient outcomes.
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Chapter 3
Robustness of Target Dose Coverage to
Motion Uncertainties for Scanned Carbon
Ion Beam Tracking Therapy of Moving
Targets
3.1

Introduction

Actively scanned carbon ion beams have been use to safely treat a number of static
tumors such as chordomas, chondrosarcomas, and osteosarcomas of the skull base, spine,
and sacrum as well as adenoid cystic carcinomas of the salivary glands (Kraft, 2000; SchulzErtner et al., 2004). Given the high tumor control rates and low toxicity observed for those
patients (Schulz-Ertner et al., 2004), there is motivation to utilize the scanned carbon ion
beam for new cancer sites, for example, non-small-cell lung cancer and hepatocellular carcinoma. Indeed, these sites have already been treated successfully with passively scattered
carbon ion beams (Tsujii et al., 2004). However, one of the strongest arguments against
using scanned ion therapy is that the dose distributions are highly sensitive to errors and
uncertainties in treatment planning and treatment delivery. For the same reasons that
scanned ion beams are beneficial, namely the sharp dose gradients and high LET found
near the ion Bragg peaks, scanned ion beams can be dangerous to patients if delivered
incorrectly. In Chapter 2, we investigated the theoretical dosimetric advantages of using
scanned carbon ion beam tracking for moving tumors, when treatment was delivered perfectly, i.e., with no errors. In this chapter, we investigate the robustness of scanned carbon
ion beam tracking in order to understand whether its theoretical benefits can persist in
the presence of uncertainties in patient motion, also considering the limited precision of a
scanned carbon ion beam tracking system.
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Several investigators have studied the robustness of scanned ion therapy to uncertainties in treatment planning, treatment delivery, and patient alignment (Pflugfelder et
al., 2007; Lomax, 2008a,b; Meyer et al., 2010). For example, if the patient is misaligned
or exhibits a change in anatomy during a course of therapy, ion Bragg peaks may miss
their planned target position, leading to potential underdosage of the target or overdose to
critical structures outside of the target. If the target is moving, interplay effects between
organ motion and ion scanning, as discussed in Section 1.4, can further complicate this
problem, potentially leading to treatment failure if adequate motion mitigation strategies
are not used (Bert and Durante, 2011). Beam tracking might enable the use of scanned
carbon ion therapy for moving tumors, but robustness analyses are needed to understand
the reliability of such a strategy.
As discussed in Section 2.1, scanned carbon ion beam tracking relies on a real-time
motion state detection system and applies tracking offsets to each scanned pencil beam
coordinate for each motion state so that the beams are steered to follow motion of the target
for all phases of respiration (Grözinger et al., 2004). Currently, beam-tracking offsets are
computed prior to treatment using a planning 4DCT. Deformable image registration vectors
are calculated from this 4DCT to map the motion of tissues throughout the respiratory
cycle, and these vector maps are used to compute tracking offsets required for each pencil
beam for each phase of respiration (Bert and Rietzel, 2007). Similar to beam gating,
this approach relies on the assumption that the planning 4DCT adequately represents the
internal motion of the patients organs during treatment delivery, and that a correlation
between the patient respiratory phase and the position of internal organs is reliable for the
duration of treatment.
It is not yet known how robust scanned carbon tracking is against errors and uncertainties in these treatment elements. Due to the high dose gradients found in scanned
carbon-ion therapy, uncertainties in organ motion and technical limitations of a beamtracking delivery system might lead to unacceptable target dose coverage when correlations
are lost between respiratory phase and internal organ position. van de Water et al. (2009)
studied beam tracking with scanned proton beams and reported deterioration of target dose
coverage when simulated time delays or position errors were introduced to tracking simulations, which was improved by combining the principles of rescanning and beam tracking.
To our knowledge, the robustness of target dose coverage to uncertainties in scanned carbon
ion beam tracking therapy for moving tumors has not been reported in the literature.
The purpose of this study was to evaluate the robustness of target dose coverage to
motion uncertainties for scanned carbon ion beam tracking therapy of moving targets. To
accomplish this, we simulated scanned carbon ion beam tracking for moving targets in both
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water phantoms and a sample of lung cancer patients using a research treatment planning
system for ion radiotherapy. We modeled various deviations from perfect tracking that
could arise due to uncertainty in organ motion and limited precision of a scanned ion beam
tracking system. We calculated 4D dose to moving targets for many combinations of these
modeled uncertainties. We also investigated the effects of interfractional changes in organ
motion on target dose coverage by simulating treatment using multi-week 4DCTs for 6 lung
cancer patients. In relation to our central hypothesis (cf. Section 1.5), this study seeks to
quantify the reliability, efficacy, and safety of 3D-optimized beam tracking, which might
one day be used to deliver scanned ion therapy to patients with thoracic tumors.

3.2

Methods

3.2.1

Robustness of Beam Tracking to Motion Uncertainties for 4 Phantoms

Design of Water Phantoms
We designed 4 mathematical phantoms with increasing degrees of complexity to evaluate scanned carbon ion beam tracking. The phantoms are shown in Figures 3.1, 3.2, and
3.3. Phantoms 1 and 2 were inspired by patients with liver cancer, i.e., a moving tumor in
relatively homogeneous tissue, and Phantoms 3 and 4 were inspired by patients with lung
cancer, i.e., a moving tumor in heterogeneous tissue. All phantoms were 10 × 10 × 10 cm3 ,
consisting of cubic voxels with dimension 1 × 1 × 1 mm3 . In all phantoms, a 3-cm diameter
spherical target oscillated with sinusoidal motion, with displacement s as a function of time
t expressed as s = Asin4 (πt/τ ) (Lujan et al., 1999). We studied respiratory periods τ of
3, 4, and 5 s. In Phantom 1, the sphere oscillated along the x-axis, perpendicular to the
beam axis (z), in a homogeneous water box with amplitude (A) of Ax = 2 cm, i.e., no
depth changes. In Phantom 2, the sphere moved in 3 dimensions, again in a homogeneous
water box, with Ax = 2 cm, Ay = 0.5 cm, and Az = 1 cm, with depth changes up to 1 cm
along the z-axis. In Phantom 3, the target moved along the x-axis in water as in Phantom
1, but a simulated rib heterogeneity was positioned upstream of the target in water to
introduce changes in radiological depths of the target voxels. The rib was approximated
as a cylinder with 1-cm diameter, inferred from anatomical cross-section measurements of
human ribs reported by Mohr et al. (2007), and 10-cm length parallel to the y-axis with
uniform Hounsfield value of 750 (Schneider et al., 2000). In Phantom 4, the rib heterogeneity of Phantom 3 was replaced by an air cavity with identical dimensions to the rib
cylinder, but with uniform Hounsfield value of -1000. For each phantom, we generated target contours, 4DCT data, and image registration vector maps to use in treatment planning,
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Figure 3.1: Schematic drawing of Phantom 1. A 3-cm spherical target (black circle) moves
sinusoidally along the x-axis (Ax = 2 cm) with no change in depth in a uniform water
phantom.
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Figure 3.2: Schematic drawing of Phantom 2. A 3-cm spherical target (black circle) moves
sinusoidally in 3D (Ax = 2 cm, Ay = 0.5 cm, Az = 1 cm,) with 1-cm change in depth in a
uniform water phantom.
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Figure 3.3: Schematic drawing of Phantoms 3 and 4. A 3-cm spherical target (black circle)
moves sinusoidally along the x-axis (Ax = 2 cm) in a water phantom. A heterogeneity
(grey shaded area) is modeled upstream of the target as a cylinder (1-cm diameter, 10-cm
length) parallel to the y-axis. For Phantom #3, the cylinder has uniform Hounsfield value
of 750, to approximate a rib. For Phantom #4, the cylinder has uniform Hounsfield value
of -1000, to represent an air cavity.
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corresponding to their unique geometry and motion characteristics.
Treatment Planning for Scanned Carbon Ion Beam Tracking
Treatment planning and 4D dose calculation for scanned carbon ion beam tracking
was performed using the TRiP4D research TPS code (Richter et al., 2013) as follows.
1 3DCT and 3D target contours for a reference motion state were loaded into the TPS.
2 A 3D scanned carbon field was planned to irradiate the target in the reference motion
state.
• A focal spot size of approximately 6.5 mm, full-width at half-maximum (FWHM),
was planned for each pencil beam. In our study, the focal spot size was defined
as the lateral beam width in air of a single pencil beam at the isocenter of
the treatment room, i.e., a reference coordinate near the middle of the patient
treatment couch.
• Pencil beam Bragg peaks were regularly spaced on a 2-mm Cartesian grid within
each isoenergy layer.
• Pencil beam energies were selected to provide a 3-mm water-equivalent depth
spacing between isoenergy layers, and a 3-mm ripple filter (Weber and Kraft,
1999) was used to blur the carbon Bragg peaks in the depth direction.
• A radial target margin of 1.1× FWHM, i.e., perpendicular to the beam central
axis, was used to ensure sufficient lateral-scatter-equilibrium to achieve target
dose coverage at the off-axis target boundary.
• A distal target margin of 4-mm water-equivalent was used to achieve target dose
coverage at the distal target boundary.
3 The numbers of carbon ions in each beam spot were optimized to achieve uniform
target dose for the 3D static case in the reference motion state.
4 4DCT and 4D image registration vectors were loaded into the TPS.
5 Beam tracking offsets were calculated for each pencil beam for each motion state so
that each pencil beam Bragg peak would remain in the same local anatomic subvolume
of the target for all motion states (see Figure 3.4).
• Lateral tracking offsets, i.e., x- and y-offsets in the beam coordinate system,
were calculated by projecting the 4D image registration vectors onto an xyplane perpendicular to the beam central axis (z).
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Figure 3.4: Diagram of perfect beam tracking and beam tracking with simulated motion
uncertainties. For perfect tracking, a set of ion pencil beams (arrows) are distributed
throughout a target volume (circle) in the reference Motion State 1 (left) with individual
Bragg peaks located in subvolumes of the target (small squares). After the target moves to
Motion State 2 (middle), each pencil beam also moves to track the subvolumes. To simulate
the effect of motion uncertainties, we offset individual pencil beam positions (right). The
offset pencil beams (right) are shown to irradiate new subvolumes (small squares) that
partially or fully miss their planned subvolumes in the target (dashed small squares), usually
leading to deterioration of the planned target dose coverage.
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• Range-tracking offsets, i.e., z-offsets, were calculated to compensate changes in
the radiological depth of the target at points coinciding with the Bragg peak
position for each pencil beam. First, 4D image-registration vectors were used to
map the movement of a subvolume in the target (e.g., a single voxel containing
a pencil beam Bragg peak) from its position in the reference motion state to
its position for all other motion states. Second, the radiological depth of that
(moving) subvolume was calculated uniquely for each motion state using an existing ray-tracing algorithm in TRiP4D and using the appropriate 3DCT subset
of the 4DCT. Finally, a range tracking offset was calculated based on the change
in radiological depth of the subvolume (containing the Bragg peak coordinate)
for all motion states.
6 Idealized patient respiratory motion signals, i.e., with constant respiratory period,
were loaded into the TPS. These motion signals were used to simulate those that
would be monitored in real-time during treatment delivery, for example using a
respirometer.
7 Beam-tracking 4D delivery was simulated.
• Based on the patient respiratory motion signal (e.g., period and starting phase),
the required particles per pencil beam, and the availability of particles from the
accelerator spill sequence, temporal characteristics of 4D delivery were simulated
by binning each pencil beam into the motion state in which it would most likely
be irradiated (Richter et al., 2013).
• The corresponding tracking offsets (from Step 5) were added to each pencil beam
Bragg peak coordinate depending on the motion state into which it was binned.
• Using new TPS codes developed in this work, errors were added to the x, y, and z
components of each tracking offset to simulate the effect of motion uncertainties,
described in further detail in the next section.
8 Finally, 4D dose was calculated by accumulating dose to voxels from all pencil beams
for all discrete motion states (Richter et al., 2013). Coordinates of the target voxels
were transformed for each motion state using the image registration vectors to allow
summation of 4D dose to the moving voxels.
For perfect tracking, we simulated 18 motion scenarios for each phantom with variation in motion trace signals with period, τ = 3, 4, and 5 s, and starting respiratory phase
at beginning of irradiation, φ = 0, 60, 120, 180, 240, and 300 degrees. Our rationale for
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these multiple motion scenarios was that, even when pencil beams perfectly track target
motion and depth changes, some deviations in off-axis dose contributions for individual
pencil beams are expected (van de Water et al., 2009). By sampling these 18 scenarios of
motion, we avoided the chance that our findings would be confounded by a single “lucky”
or “unlucky” choice of τ or φ.
Simulation of Motion Uncertainties and Beam Tracking Uncertainties
We modeled both systematic and random positional uncertainties as well as temporal
lags during beam tracking therapy. Ultimately, uncertainties were simulated by shifting
pencil beam coordinates and modifying target motion signals prior to 4D dose calculation
as illustrated in Figure 3.4. For each individual uncertainty modeled, we also included 18
motion scenarios of respiration with variable period and starting phase as described for the
perfect tracking case above. A list of modeled uncertainties and a brief description of our
rationale and implementation in our TCS is given below.
A Phase Delays in Beam Tracking
• Rationale: Delays in applying the correct tracking offset to individual pencil
beams for given motion states might be caused either by delays in the motion
state detection system or by delays in the beam tracking control system or beam
delivery system.
• Implementation: Delays were simulated by loading both an internal motion
signal (i.e., representing the “true” tumor motion) and an external motion signal
(e.g., that could represent motion of an external surrogate marker) into the TPS
(Richter et al., 2013). The internal motion signal was used to synchronize the
temporal delivery of pencil beams to their appropriate 4DCT motion state for
4D dose calculation (see Step 7 above), but the external motion signal was used
to determine a given beam tracking offset. By delaying the external motion
signal, we caused tracking offsets to be applied from an incorrect motion state,
depending on the amount of delay.
• Variables Simulated: Phase delays of 0, 5, 10, and 15 degrees were simulated.
B Random Errors in Pencil Beam Coordinates
• Rationale: Random errors in pencil beam coordinates during beam tracking
might be caused by limited precision of the beam tracking system, i.e., scanner
magnets and range-tracking wedge.
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• Implementation: Random errors were sampled from Gaussian distribution with
a user specified width σ using a random number generator and added to pencil
beam tracking offsets prior to 4D dose calculation.
• Variables Simulated: We applied 1D random errors independently to x, y, and z
with σ of 0, 0.5, 1.0, and 1.5 mm. We also applied combined 3D random errors
to x, y, and z with σ values of 0, 0.5, 1.0, and 1.5 mm.
C Systematic Errors in Pencil Beam Coordinates
• Rationale: Systematic errors in pencil beam coordinates during beam tracking
therapy might be caused by misalignment of the patient, patient shifting after
setup, or by weight loss of the patient.
• Implementation: Systematic errors were added to pencil beam tracking offsets
prior to 4D dose calculation.
• Variables Simulated: We applied 1D errors of 0, 1, 2, 3, and 4 mm independently
to x, y, and z pencil beam coordinates. We also applied combined 3D errors of
0, 1, 2, 3, and 4 mm simultaneously to x, y, and z pencil beam coordinates.
D Limited Acceleration of Range-tracking Wedge System
• Rationale: When a motion state change occurs or a new pencil beam begins
irradiation, a new range-tracking offset must be applied. The tracking system
at GSI uses a passive acrylic wedge system mounted on linear drive motors that
move material in or out of the beam path. This motorized system has a finite
acceleration of 8 g (1 g = 9.81 m/s2 ), i.e., in water-equivalent range changes,
(Saito et al., 2009) that delays immediate application of the range-tracking offset.
• Implementation: We implemented equations for 1D motion of the range-tracking
wedge under the influence of constant acceleration, constant deceleration, or
no acceleration into our TPS. When a new tracking range-offset was requested
during treatment simulation, e.g., when a new pencil beam started irradiation or
a motion state change occurred, we considered the current position and velocity
of the range-tracking wedge and simulated its trajectory that would allow it to
most quickly reach and stop at the desired new position. From this trajectory we
determined the mean wedge-position for each pencil beam for each motion state
and used that mean position as the range-tracking offset for our simulations.
• Variables Simulated: We simulated range-tracking wedge acceleration values of
0.001, 0.01, 0.1, 1, 8, 10, and 100 g and a hypothetical wedge with infinite
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acceleration. The infinite acceleration wedge was used for our reference case
simulations. Acceleration was defined along the beam central axis (z) in terms
of changing water-equivalent thickness of the acrylic wedge in the beam path.
Analysis of Computed Dose Distributions
In order to analyze the large number of simulations performed in our robustness
study for scanned carbon beam tracking, we wrote Linux scripts to extract dose-volume
statistics from each treatment simulation record and to automatically plot these dosevolume statistics. All 4D dose distributions were transformed to a reference 3D motion
state for analysis. For each phantom and each variable studied, we combined the target
dose distributions for the 18 scenarios of possible respiratory patterns. From these combined
distributions, we prepared box-whisker plots to allow easy visualization of the entire range
of target dose distribution expected for a single modeled uncertainty. We also determined
the volume of the target receiving at least 95% of the prescribed dose (V95 ), the volume
of target receiving greater than 107% of the prescribed dose (V107 ), and D5 − D95 , the
difference between the highest dose in the target, after excluding 5% of the target volume
receiving the very highest dose, and the lowest dose in the target, after excluding 5% of
the target volume receiving the very lowest dose. V95 was used to quantify target dose
coverage, V107 was used to quantify target overdosage, and D5 − D95 was used to quantify
target dose homogeneity. For select cases, we plotted 2D cuts from the dose distributions
as colorwash overlaying the phantom and target contours.
3.2.2

Robustness of Beam Tracking to Simulated Motion Uncertainties for 1
Lung Patient

We simulated the impact of motion uncertainties on target dose coverage for Lung
Patient #1, who had a peak-to-peak tumor motion amplitude of 25 mm, as discussed in
Section 2.2.3. For this lung cancer patient, treatment planning for scanned carbon beam
tracking was similar to that described for the water phantoms in Section 3.2.1, with the
following differences. Instead of 1 field, we used the 4-field irradiation protocol developed
at NIRS for hypofractionated lung cancer therapy with carbon beams (Miyamoto et al.,
2007). We used gantry angles of +20, -20, -70, and -110 degrees that corresponded to the
angles used at NIRS. For reference, in TRiP4D, 0 degrees represents a lateral beam and
-90 degrees represents an AP beam. The couch angle was -90 degrees, hence all beams
fell in an axial plane. We used the Local Effect Model Version IV at GSI (Scholz et al.,
1997; Elsässer et al., 2010) along with TRiP4D to optimize and calculate RBE-weighted
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carbon dose distributions, i.e., with the biological endpoint of lung tumor control. We
used an α/β ratio of 6 Gy for lung tumor control (α = 0.021 Gy−1 , β = 0.0035 Gy−2 ,
DT = 10 Gy) (Lüchtenborg, 2011). We planned 8.2 Gy (RBE) for each of the 4 fields for
a total dose of 32.8 Gy (RBE) to the target. We used a combination of both rigid image
registration vectors and deformable image registration vectors to plan beam tracking offsets
and to calculate 4D accumulated dose, respectively. Lüchtenborg (2011) demonstrated that
keeping a rigid spacing between neighboring pencil beams can provide a more homogeneous
target dose for beam tracking, since a deforming grid can lead to bunching and dispersion of
pencil beams that causes local overdosing and underdosing within the target, respectively.
Thus, we used rigid vectors to plan beam tracking offsets, but we used deformable image
registration vectors in the 4D dose calculations. For calculation of rigid image registration
vectors, we only considered motion of tissue within the CTV boundary. For calculation of
deformable image registration vectors, we used the entire 4DCT data set.
For Lung Patient #1, motion uncertainties and beam tracking uncertainties were
simulated identical to those described for the water phantom studies in Section 3.2.1.
Analysis of target dose distributions was similar to that described for the water phantoms.
In all cases, the 4D dose distributions from the combined 4 fields were transformed to a
3D reference motion state at end-exhale for analysis. In addition, we also plotted the full
distribution of beam tracking offsets required for each pencil beam and each motion state.
3.2.3

Robustness of Beam Tracking to Interfractional Changes in Organ Motion for 6 Lung Cancer Patients

Rationale
One serious criticism of scanned ion beam tracking is that the approach currently
assumes true periodic organ motion and that there exists a fixed correlation between the
patient respiratory phase and the motion of internal anatomy. For example, if only external
motion surrogates, such as markers fixed to the sternum, were monitored during treatment
delivery, an internal motion deviation might be missed. If drifts in absolute tissue position
would occur, e.g., due to muscle relaxation over the course of several minutes, then respiratory phase alone may not accurately be used to predict the position of internal organs.
In addition, weight loss of the patient during a course of treatment likely leads to changes
in the range of ion pencil beams in tissue. Therefore, we sought to better understand
the dosimetric consequences of relying on these assumptions by simulating scanned carbon
beam tracking treatment using an initial 4DCT for treatment planning and then using a
multiple-week series of 4DCT images, acquired for the same set of patients, to simulate
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treatment and delivery of 4D dose distributions to the patients at later time points.
Patient Sample
To study the effects of interfractional changes in organ motion on target dose coverage
for scanned carbon beam tracking, we selected 6 lung cancer patients who were previously
enrolled in a research study at UTMDACC and had undergone multi-week serial 4DCT
imaging. These patients received a 4DCT imaging sequence each week following the methods of Pan et al. (2004), with images binned into 10 phases of their respiratory cycle. Our
approach was to prepare a scanned carbon ion beam tracking treatment plan using the first
4DCT image set and, then, to simulate treatment delivery using the later 4DCT image sets.
Treatment Planning and Simulation on Multi-week 4DCTs
We used the software program Plastimatch (Shackleford et al., 2010) to calculate
deformable image registration vectors for each patient for each 4DCT image series to use in
4D dose calculation. We calculated rigid image registration for all phases of the first 4DCT
set to plan beam tracking offsets as described in Section 3.2.2. In addition, we rigidly
registered the patient position at a reference state of end-exhale throughout all weeks of
4DCT images. From this, we rigidly offset the CT voxel coordinates when simulating
treatment on later week 4DCTs. This concept is similar to aligning the patient before each
treatment, e.g., using an onboard imaging device such as orthogonal x-ray planar images
or cone-beam CT images. Treatment plans were prepared as described in Sections 3.2.1
and 3.2.2, again using 4 fields and 32.8 Gy (RBE) total dose. For patients with targets
in the right lung, the couch angle was changed from -90 to 90 degrees. For calculation of
dose on later 4DCTs, the correct 4DCT and corresponding deformable image registration
vector map was loaded into the TPS just before calculating 4D dose. For 6 patients, we
calculated dose on 3 4DCTs, i.e., week 0, 1, and 2. For Lung Patient #1, we also used a
second 4DCT scan from week 0 to investigate interfractional motion changes that might
occur during a single day, however, this data was not available for the other 5 patients in
our study. For each treatment simulation, we used 18 different respiratory motion signals
with variable period and starting phase as described in Section 3.2.1.
Analysis of Computed Dose Distributions
Analysis of target dose distributions was similar to that described for the water phantoms. In all cases, the 4D dose distributions from the combined 4 fields were transformed
to a 3D reference motion state at end-exhale for analysis.

58

3.3

Results

Target dose coverage for scanned carbon ion beam tracking was found to be sensitive
to a number of independently varying errors in beam tracking. As expected, robustness of
target dose coverage to these errors in beam tracking was generally poorer when heterogeneities were present near the target. However, robustness was generally better for patient
plans, where we used 4 equal-weight beams, compared to the mathematical phantom plans
with simulated heterogeneities, where we used only a single beam. Overall, target dose was
found to be most sensitive to phase delays in beam tracking, systematic spatial errors in
tracking, and interfractional changes in organ motion. Limited acceleration of the rangetracking wedge was found to have a moderate impact on target dose coverage, particularly
for the lung patient. Random errors in beam tracking were found to have minimal impact
on target dose coverage.
In the following sections, we present our dose calculations for scanned carbon ion beam
tracking for each modeled error in beam tracking. First, we present dose-colorwash plots to
illustrate our treatment plans for perfect tracking scenarios. Then, we present dose-volume
statistics for the moving targets for all cases of simulated errors in beam tracking. We also
present tables to summarize the robustness of V95 , our main metric for target coverage, as
a function of the simulated errors in beam tracking. Finally, we present the robustness of
target dose coverage to interfractional changes in organ motion for 6 lung cancer patients.
3.3.1

Robustness of Beam Tracking to Motion Uncertainties for 4 Phantoms

Target Dose Distributions for Perfect Tracking
For our simulations of perfect beam tracking (for the motion scenario with τ = 4 s and
φ = 0 degrees), we found a highly uniform and nearly identical target dose for Phantoms
#1 and #2 with mean target doses of 100 ± 1 %, i.e., percent of the prescribed target dose,
for both phantoms. However, we found slightly non-uniform target dose for Phantoms #3
and #4, which both had a cylindrical heterogeneity upstream of the moving target, with
mean target doses of 100 ± 3 % and 99 ± 5 %, respectively. Dose distributions are shown
as 2D colorwash cuts in the XZ plane in Figure 3.5 for perfect tracking. Dose-volume
statistics for perfect tracking are shown in Figure 3.6, at points where the phase delay is 0
degrees (i.e., no delay). We observed that the target dose coverage for perfect tracking for
Phantoms #1 and #2 was not affected by respiratory period or starting phase, and all 18
data points (for the 18 scenarios of respiratory motion with variable period (τ ) and starting
phase (φ)) overlay exactly. However, for Phantoms #3 and #4, we observed differences
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a

b

c

d

Figure 3.5: Perfect beam tracking dose distributions in XZ plane shown for a reference
scenario (τ = 4 s and φ = 0 degrees) for Phantom #1 (a), Phantom #2 (b), Phantom #3
(c), and Phantom #4 (d). Target indicated by large white circle. Beam direction was −z.
For Phantoms #3 and #4, a proximal slab (z in 80-100 mm) did not move and contained
the rib cylinder and air cylinder heterogeneities, respectively, indicated by the small white
circles. Irregular dose distributions are seen in the target for Phantoms #3 and #4 even
for perfect tracking.
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Phantom #1
Phantom #2
Phantom #3
Phantom #4

Figure 3.6: Robustness of target dose coverage to phase delays in tracking shown for the
4 phantoms. Each box-whisker plot (top left) summarizes the minimum, first quartile,
median, third quartile, and maximum target dose (values are percent of prescribed dose)
over all 18 scenarios of motion (with variable period τ and starting phase φ) for each value
of phase delay. Dose-volume statistics for each of the 18 individual motion scenarios are
shown by the markers for V95 , V107 , and D5 − D95 for each value of phase delay. Dose and
volume values are reported as percent of prescribed target dose and percent of total target
volume, respectively. Markers are offset slightly to ease viewing. For all phantoms, target
dose coverage (V95 ) degrades rapidly with increasing phase delays in beam tracking.
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in target dose coverage for those 18 scenarios depending on the respiratory period and
respiratory starting phase. Thus, even for perfect tracking, target dose coverage was found
to be degraded by heterogeneous tissue upstream of the moving target.
Phase Delays in Beam Tracking
The robustness of target dose coverage to simulated phase delays in beam tracking
is shown in Figure 3.6. A rapid degradation of target dose coverage (V95 ) with increasing
phase delay is seen for all 4 phantoms. For an example, if the respiratory period were 4
s, these phase delays of 5, 10, and 15 degrees would correspond to temporal delays of 56,
111, and 167 ms, respectively. Such phase delays in beam tracking could potentially arise
either in real-time detection of a patients current motion state or in real-time application
of tracking offsets with the beam delivery system.
Random Errors in Beam Tracking
The impact of random spatial errors in beam tracking on target dose coverage was
found to be minimal (V95 changed less than 1%) when errors were sampled from Gaussian
distributions with σ ≤ 0.5 mm (cf. Table 3.1). Furthermore, only slight degradation of
target dose coverage was seen with random errors sampled with σ values up to 1.5 mm. For
reference, the precision in lateral x and y pencil beam spot position for beam tracking, as
determined by the dipole scanning magnets and position feedback system, is approximately
0.16 mm for the GSI carbon ion synchrotron, and the precision in the z range-tracking
offsets, determined by the water-equivalent pathlength through the range-tracking wedge
system, is approximately 0.25 mm (Saito et al., 2009). Plots of the robustness of target dose
coverage to random errors in beam tracking for the phantoms are included in Appendix A.
Systematic Errors in Beam Tracking
Target dose coverage was found to be highly sensitive to systematic spatial errors in
beam tracking. Errors up to 4 mm led to an approximately 21% drop in target coverage
V95 , averaged over all phantoms. Figure 3.7 shows the robustness of target dose coverage
to combined systematic errors in tracking x-, y-, and z-coordinates. Results for individual
systematic errors in tracking x-, y-, and z-coordinates are included in Appendix A. For
Phantoms #1 and #2, minimal effect on target dose was seen until the errors were greater
than 2 mm, with visible drops in coverage with errors of 3 and 4 mm, likely caused when the
scanned ion field edge moves very close to the target boundary. In contrast, for Phantoms
#3 and #4, loss of target dose coverage is seen even for 1 mm systematic errors and increases
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Table 3.1: Robustness of target dose coverage to tracking errors for 4 phantoms. V̄95 is the
mean V95 for 4 phantoms and 18 motion scenarios. Changes in coverage (∆V̄95 ) more than
5% indicated in red. Derivative is the change in V̄95 per unit error.

Variable (units)

Error Magnitude V̄95 (%)

Perfect Tracking
Phase Delay (degrees)

5.0
10.0
15.0
Random X Offset (mm)
0.5
1.0
1.5
Random Y Offset (mm)
0.5
1.0
1.5
Random Z Offset (mm)
0.5
1.0
1.5
Random XYZ Offset (mm)
0.5
1.0
1.5
Systematic X Offset (mm)
1.0
2.0
3.0
4.0
Systematic Y Offset (mm)
1.0
2.0
3.0
4.0
Systematic Z Offset (mm)
1.0
2.0
3.0
4.0
Systematic XYZ Offset (mm) 1.0
2.0
3.0
4.0
Wedge Acceleration (g)
0.001
0.01
0.1
1
8
10
100

94.8
83.1
76.4
72.8
93.9
90.7
86.2
93.9
90.9
86.5
95.2
95.6
95.7
93.3
87.1
80.6
93.1
90.8
88.0
84.3
94.7
94.5
93.4
90.9
94.5
94.0
93.0
91.1
92.7
88.8
82.3
74.3
75.6
81.3
86.0
93.1
94.6
94.6
94.7
63

∆V̄95 (%)

Derivative (%/unit)

-11.7
-18.4
-22.0
-0.9
-4.1
-8.6
-0.8
-3.9
-8.2
0.5
0.9
0.9
-1.5
-7.6
-14.2
-1.6
-3.9
-6.8
-10.4
0.0
-0.2
-1.4
-3.9
-0.3
-0.8
-1.7
-3.7
-2.0
-5.9
-12.5
-20.5
-19.2
-13.5
-8.8
-1.6
-0.2
-0.2
0.0

-2.3
-1.3
-0.7
-1.8
-6.3
-9.1
-1.7
-6.1
-8.7
0.9
0.8
0.2
-2.9
-12.3
-13.1
-1.6
-2.3
-2.9
-3.6
-0.0
-0.2
-1.1
-2.5
-0.3
-0.5
-0.9
-1.9
-2.0
-3.9
-6.6
-8.0
637.8
52.0
7.9
0.2
0.0
0.0

Phantom #1
Phantom #2
Phantom #3
Phantom #4

Figure 3.7: Robustness of target dose coverage to systematic errors in tracking x-, y-, and
z-coordinates shown for the 4 phantoms. A rapid deterioration of target dose coverage
(V95 ) with increasing offset is seen for Phantom #4 and, to a lesser extent, Phantom #3
even for offsets as little as 1 mm. Phantoms #1 and #2 showed a greater robustness to
systematic errors but target dose coverage also degraded with shifts greater than 2 mm.
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Phantom #1
Phantom #2
Phantom #3
Phantom #4

Figure 3.8: Robustness of target dose coverage to to limited acceleration of the rangetracking wedge shown for the 4 phantoms. Note that Phantom #1 (black markers) did not
require any range tracking, and, therefore, dose coverage does not depend on range-tracking
acceleration. (1 g = 9.81 m/s2 )
with the amount of error. This effect was dominated by x-axis errors in tracking (cf. Table
3.1), since relatively small x-shifts introduced comparably large changes in radiological
depth of the target due to the cylindrical heterogeneities present upstream of the target
for Phantoms #3 and #4. Therefore, the robustness of beam tracking to systematic errors
was poorer when heterogeneities were present.
Limited Acceleration of Range-tracking Wedge
For the 4 phantoms, we found target dose coverage to be mostly insensitive to wedge
acceleration for a ≥ 8 g (1 g = 9.81 m/s2 ). However, for acceleration less than 1 g,
target dose coverage deteriorated with decreasing acceleration. Note that the direction
of acceleration is reported not in the direction of wedge motion but rather in the beam
direction, i.e., quantifying the change in water-equivalent pathlength through the acrylic
wedge. Figure 3.8 shows the robustness of target dose coverage when we simulated variable
acceleration of the range-tracking wedge system. Our reference case of perfect tracking
was modeled with infinite wedge acceleration. To put these numbers in perspective, the
range tracking wedge system implemented at GSI can modify the beam range with an
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Figure 3.9: Perfect beam tracking offsets for Lung Patient #1 for Field #1. Pencil beam
x-offsets (green), y-offsets (blue), and z-offsets (red) are shown for each pencil beam for
each motion state. Note the x-offsets of up to approximately 25 mm correspond directly
to SI target motion. z-offsets (i.e., range-offsets) exhibit a more complex pattern due to
motion of the target in heterogeneous tissue. The reference motion state was 5.
acceleration of approximately 8 g (Saito et al., 2009).
3.3.2

Robustness of Beam Tracking to Simulated Motion Uncertainties for 1
Lung Patient

Example of Beam Tracking Offsets Calculated for Perfect Tracking
The robustness of scanned carbon ion beam tracking to tracking errors in patient cases
can be better understood by looking at an exemplary distribution of tracking parameters
needed for a lung tumor moving in heterogeneous tissue. Figure 3.9 shows the distribution
off beam tracking offsets required for Lung Patient #1 for Field #1 (gantry angle of -20 degrees) for all pencil beams and all motion states for perfect tracking. The x tracking offsets
compensated SI motion of up to approximately 25 mm, while y tracking offsets compen-

66

sated mainly AP motion up to approximately 5 mm. The z offsets compensated changes
in radiological depth of the target tissue, requiring up to 25 mm of range-compensation
in some motion states, with large variations in range tracking needed for different pencil
beams within single motion states. These large fluctuations in range-tracking offset values put high technical demands on the treatment delivery system for patient cases, e.g.,
when a tumor moves in heterogeneous lung tissue, and are a concerning factor for tracking
robustness.
Target Dose Distributions for Perfect Tracking
Our treatment plan for Lung Patient #1 is shown in Figure 3.10 with 2D cuts of 4D
RBE-weighted dose overlaying CT images in the reference motion state at end-exhale for
perfect beam tracking (τ = 4 s and φ = 0 degrees). We observed a uniform target dose
coverage of 32.7±1.1 Gy (RBE) with a rapid falloff of dose outside the target volume. Dosevolume statistics for perfect tracking (for all 18 scenarios of variable respiratory period and
starting phase) are shown in Figure 3.11, at points where the phase delay is 0 degrees (i.e.,
no delay). Similar to Phantom #3 with the rib heterogeneity, some dependence of target
dose coverage on respiratory period and starting phase is seen even for perfect tracking,
though not as much as that seen for Phantom #4 with the air heterogeneity. These 18 dose
distributions provide our baseline estimate of target dose coverage (V̄95 = 95.5%) for perfect
beam tracking for Lung Patient #1, against which we compare our dose distributions with
simulated errors in tracking, discussed in the remainder of this section and summarized in
Table 3.2.
Phase Delays in Beam Tracking
Target dose coverage was found to be highly sensitive to phase delays in beam tracking. Figure 3.11 shows the robustness of target dose coverage to simulated phase delays up
to 15 degrees, which led to drops in target dose coverage (V̄95 ) up to 18%. These findings
were similar to those in our phantom study (cf. Section 3.3.1). Thus, phase delays in tracking were a major detriment to target dose coverage for beam tracking for both phantom
and patient cases.
Random Errors in Beam Tracking
The impact of random spatial errors in beam tracking on target dose coverage for
the lung patient was found to be minimal (V̄95 changed less than 1%) when errors were
sampled from Gaussian distributions with σ ≤ 1 mm (cf. Table 3.2). Compared with the
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Figure 3.10: 4D RBE-weighted dose distributions overlaying CT images for the reference
case of perfect beam tracking for Lung Patient #1 with axial (top), coronal (bottom left),
and sagittal (bottom right) views. 4D RBE-weighted dose and CT data are shown in the
reference motion state at end-exhale. The CTV boundary is indicated by the white curve.
The prescribed target dose was 32.8 Gy (RBE). This plot shows the treatment plan but
does not contain information about robustness.
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Figure 3.11: Robustness of target dose coverage to phase delays in tracking shown for Lung
Patient #1. Target coverage decreases with increasing phase delay, as seen in V95 (top
right). An increase in overdosed volumes, as quantified by V107 (bottom left), might be
attributed to interplay effects that occur when lagging pencil beams have incorrect lateral
coordinates or incorrect range coordinates.
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Table 3.2: Robustness of target dose coverage V̄95 to tracking errors for Lung Patient #1.
V̄95 is the mean V95 for 4 phantoms and 18 motion scenarios. Changes in coverage (∆V̄95 )
more than 5% indicated in red. Derivative is the change in V̄95 per unit error.

Variable (units)

Error Magnitude V̄95 (%)

Perfect Tracking
Phase Delay (degrees)

5.0
10.0
15.0
Random X Offset (mm)
0.5
1.0
1.5
Random Y Offset (mm)
0.5
1.0
1.5
Random Z Offset (mm)
0.5
1.0
1.5
Random XYZ Offset (mm)
0.5
1.0
1.5
Systematic X Offset (mm)
1.0
2.0
3.0
4.0
Systematic Y Offset (mm)
1.0
2.0
3.0
4.0
Systematic Z Offset (mm)
1.0
2.0
3.0
4.0
Systematic XYZ Offset (mm) 1.0
2.0
3.0
4.0
Wedge Acceleration (g)
0.001
0.01
0.1
1
8
10
100

95.5
86.9
79.2
77.2
95.5
95.6
95.4
95.4
95.2
94.9
95.9
96.4
96.6
95.8
96.1
95.9
95.0
94.1
92.5
90.4
95.4
94.9
93.6
91.6
95.6
95.2
94.5
93.6
94.9
92.7
87.7
79.6
79.0
79.7
87.5
90.3
90.5
90.7
95.2
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∆V̄95 (%)

Derivative (% / unit)

-8.7
-16.3
-18.3
0.0
0.1
-0.1
-0.1
-0.3
-0.7
0.3
0.9
1.1
0.3
0.6
0.4
-0.5
-1.4
-3.0
-5.2
-0.1
-0.6
-1.9
-3.9
0.0
-0.3
-1.0
-1.9
-0.6
-2.8
-7.8
-15.9
-16.5
-15.8
-8.0
-5.2
-5.0
-4.8
-0.3

-1.7
-1.5
-0.4
0.1
0.0
-0.3
-0.2
-0.4
-0.8
0.7
1.0
0.4
0.6
0.5
-0.4
-0.5
-1.0
-1.6
-2.1
-0.1
-0.5
-1.2
-2.0
0.1
-0.4
-0.7
-0.9
-0.6
-2.3
-5.0
-8.2
78.1
86.3
3.1
0.0
0.1
0.0

Figure 3.12: Robustness of target dose coverage to systematic errors in tracking x-, y-, and
z-coordinates shown for Lung Patient #1. A more dramatic decrease in V95 and increase
in D5 − D95 is seen, compared to systematic offsets in 1D only (cf. Figures A.12 and A.14).
phantoms, even less effect was seen in Lung Patient #1, likely due to averaging effects for
the 4 beams. As discussed in Section 3.3.1, the precision in beam tracking is better than
0.3 mm for the experimental system at GSI. Plots of the robustness of target dose coverage
to random errors in beam tracking for the lung patient are included in Appendix A. We
determined that random spatial errors in beam tracking had negligible impact on target
dose coverage for the precision of our tracking system.
Systematic Errors in Beam Tracking
Target dose coverage was found to be highly sensitive to systematic spatial errors in
beam tracking. Errors up to 4 mm led to an approximately 16% drop in target coverage
V95 , averaged over all phantoms. Figure 3.12 shows the robustness of target dose coverage
to combined systematic errors in tracking x-, y-, and z-coordinates. Results for individual
systematic errors in tracking x-, y-, and z-coordinates are included in Appendix A. Only
minimal effect on target dose (< 3% change in V̄95 ) were seen until the errors were greater
than 2 mm, with larger drops in target dose coverage and slight loss of dose homogeneity
for errors of 3 and 4 mm, as the scanned ion field edge approaches the target boundary. The
drop in target coverage V95 due to systematic errors for Lung Patient #1 was less dramatic
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Figure 3.13: Robustness of target dose coverage to limited acceleration (a) of the rangetracking wedge shown for Lung Patient #1. A moderate drop in target dose coverage V95
is seen for a < 100 g and further worsening is seen for a < 1 g.
than for either of the phantoms with heterogeneities (cf. Figure A.5), likely explained by
blurring out of dose errors by the 4 fields. Overall, the robustness of beam tracking to
systematic errors was better for the patient case compared to the phantoms but still a
major concern.
Limited Acceleration of Range-tracking Wedge
For Lung Patient #1, target dose coverage was degraded due to limited acceleration of the range tracking wedge, except for very high wedge acceleration (e.g., a > 100 g).
Figure 3.13 plots the robustness of target dose coverage to limited acceleration of the rangetracking wedge for the patient. The reference case of perfect tracking was represented by
infinite wedge acceleration. Simulation of 100 g wedge acceleration produced nearly identical target dose coverage to that with infinite wedge acceleration. For wedge acceleration
of 1 to 10 g, similar target dose coverage V95 is seen approximately 5% lower than that
seen for perfect tracking (cf. Table 3.2). At wedge accelerations below 1 g, target dose
coverage deteriorates even further with decreasing wedge acceleration. The range-tracking
wedge system implemented for experiments at GSI has an acceleration of approximately 8
g and, thus, might not achieve desired target dose coverage for lung patients unless further
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solutions are devised.
3.3.3

Robustness of Beam Tracking to Interfractional Changes in Organ Motion for 6 Lung Cancer Patients

Target dose coverage was found to deteriorate greatly due to interfractional changes
in organ motion 1 and 2 weeks post-planning, as studied for 6 lung cancer patients using
multi-week 4DCTs. To give an overview of these patients and the variety of lung tumors
studied, Figure 3.14 shows our treatment plans overlaying CT images from the initial
planning 4DCT (week 0), i.e., for perfect tracking (τ = 4 s and φ = 0 degrees). Figure
3.15 shows the robustness of target dose coverage to interfractional motion changes for the
6 lung patients. The median target dose remained stable for all patients, within 4 % of the
prescribed dose, even up to 2 weeks after planning. However, target dose coverage (V95 )
deteriorated with time post-planning. For all 6 patients (and for the 18 motion scenarios),
V̄95 dropped from 94.3% at week 0 to 85.9% and 86.2% for treatment simulated 1 and
2 weeks after planning, a mean decrease in V̄95 of 8.4% and 8.1%, respectively. Target
dose coverage deteriorated more with time post-planning for Patients #1 and #2, who
had the greatest motion amplitudes (up to 25 mm). Overall, target dose coverage (V95 )
was degraded by interfractional changes in organ motion though median target dose was
approximately stable. While this chapter focuses on the robustness of 3D-optimized beam
tracking, we also performed similar calculations to those described here to investigate the
robustness of 4D-optimized beam tracking to interfractional changes in organ motion for
Lung Patient #1. Those results are included in Table A.1 in Appendix A.
3.3.4

Summary of Results

• For simulations of perfect tracking of moving targets in heterogeneous matter, we
found that dose distributions were sensitive to the phase of respiration at the start of
irradiation and to the respiratory period. Even when the pencil beam Bragg peaks
were directed to perfectly track the moving target, off-axis dose contributions from
individual pencil beams were affected by variation in tissue upstream of the moving
target and dose was degraded. This finding is in agreement with the findings of van de
Water et al. (2009).
• Phase delays in tracking the moving targets led to large degradation of target dose
coverage. This finding supports the need for predictive algorithms for motion tracking
and fast, i.e., few ms, hardware to apply beam tracking parameters in real time during
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(a)

(b)

(c)

(d)

(e)

(f)

Figure 3.14: Axial view of RBE-weighted dose overlaying CT shown for Lung Patients #1 #6, indicated by (a) - (f), respectively, for perfect tracking for a reference case with τ = 4 s
and φ = 0 degrees. This figure gives a view of our treatment plans and shows the variation
in patient anatomy and tumor size for our 6 lung patients.
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Patient #1
Patient #2
Patient #3
Patient #4
Patient #5
Patient #6

Figure 3.15: Robustness of target dose coverage to interfractional motion changes shown
for the 6 lung patients. All treatment plans were prepared for an initial 4DCT Series #1,
and dose was also calculated using the later 4DCTs. 4DCT Series #2 was acquired for only
Patient #1 on the same day as the initial 4DCT. For all patients, 4DCT Series #3 was
acquired 1 week after the initial 4DCT, and 4DCT Series #4 was acquired 2 weeks after
the initial 4DCT. Target dose coverage V95 deteriorated with time post-planning, dropping
approximately 8% after 1 week.
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treatment.
• Random tracking errors sampled from a Gaussian distribution with σ < 0.5 mm had
almost no effect on target dose coverage.
• Systematic errors in beam tracking, which could represent patient misalignment, baseline drifts in target position, or errors in image registration used for planning, caused
two distinct ill effects on target dose coverage. First, simple misalignment of the target with the radiation field boundary led to underdosage of the target, as the target
moved near the dose falloff region. This degradation was observed with errors greater
than 2 mm and could likely be addressed simply by using treatment margins, similar
to a PTV concept. Second, a more complex relation was seen in heterogeneous tissue,
and even relatively small, e.g., 1 mm, errors led to degraded dose, likely since the
radiological thickness of tissue upstream of the target can vary greatly off axis. Thus,
lateral misalignment of a pencil beam can manifest as an incorrect depth of its Bragg
peak in a complex manner.
• The limited acceleration of the range-tracking wedge led to minimal degradation of
target dose when acceleration was ≥ 8 g for phantoms. We observed an inflection and
rapid worsening of target dose when acceleration was ≤ 1 g. Our patient simulations
suggest that a higher wedge acceleration > 10 g might be required to improve target
dose coverage, but our data do not suggest the need for acceleration greater than 100
g. If very fast range-tracking is needed in the future, the method of Chaudri et al.
(2010), which uses magnetic beam deflection and a static wedge degrader, might be
preferable to the motorized wedge system used in this study.
• For the 6 lung cancer patients in our study with multi-week 4DCTs, interfractional
changes in organ motion did not lead to large changes in the median target dose, i.e.,
median dose was within 4% of that prescribed, even up to 2 weeks after planning.
However, as expected, dose coverage (V95 ) worsened with time, dropping approximately 8% after 1 week post-planning. Larger degradation of dose coverage was
observed for patients with greater tumor motion. For Lung Patient #1, V95 dropped
approximately 7% due to variation in organ motion occurring during a single day.
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3.4

Discussion

In this study, we evaluated the robustness of target dose coverage to motion uncertainties for 3D-optimized scanned carbon ion beam tracking therapy for moving targets.
We implemented codes in a research TPS to allow simulation of a number of deviations
from perfect tracking. Additionally, we investigated the robustness of beam tracking to
interfractional changes in organ motion using multiweek 4DCTs for a sample of lung patients. We found target dose coverage for scanned carbon ion beam tracking therapy to be
sensitive to a number of simulated motion uncertainties. Sensitivity was minimal for the
lung cancer case against technical uncertainties even though no setup or motion margins
were used. Higher sensitivity was seen with respect to changes of anatomy as studied in the
multiweek analysis. Our findings can be used to inform the design specifications of future
scanned ion beam tracking systems and to inspire future motion mitigation strategies.
One major strength of this work is that this approach gives a view of the motion
problem that cannot be explored using commercial treatment planning systems. By the
thousands (nearly 4000 dose calculations were reported in this chapter) of 4D dose calculations possible using a research TPS and a research computing cluster, we were able to
isolate variables and model the specific impacts of these variables on target dose coverage
for patients with moving tumors receiving scanned carbon ion therapy. Another strength
is that many of these methods are general and might also be used to simulated the effect of
motion uncertainties on dose for other motion mitigation strategies for scanned ion therapy,
such as beam gating or rescanning. In this work, we evaluated the robustness of target dose
coverage for moving phantoms and lung patients without using setup or motion margins,
i.e., no “PTV-type” margins, which could mask underlying changes to the desired dose
distribution caused by small errors in beam tracking. This means that our results can be
used to understand the baseline robustness of scanned carbon beam tracking and also be
used to decide margins and precision requirements that best ensure robustness of target
dose coverage for future patient treatments.
Our finding of imperfect target dose coverage even for perfect tracking agreed with
that reported by van de Water et al. (2009). However, their study did not include patient
simulations, whereas we found target dose coverage to be more robust to tracking errors
in patient anatomy compared with our mathematical phantoms. These heterogeneous
phantoms could be viewed as a worst case example since such cylindrical geometries with
discrete edges are rarely found in patients. Since we found target dose coverage to depend
on patient starting phase and respiratory period, even for perfect tracking, we expect that
rescanning with beam tracking, as suggested by van de Water et al. (2009) would likely
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provide a more robust dose coverage for targets moving in heterogeneous tissue.
Our study had several limitations. One limitation was that we only investigated
robustness to technical uncertainties for one lung patient, who had the highest motion
amplitude in our sample of 6 patients. Thus, we might overestimate the sensitivity of
target dose coverage to errors in tracking compared to that possible for patients with
reduced tumor motion. Another limitation was that we performed 4D dose calculations
using a central-axis pencil beam dose algorithm for scanned carbon-ion therapy, which likely
introduced systematic errors in our dose distributions when heterogeneities were present
near, but off-central-axis, to the ion pencil beams. However, in this study, the speed of the
pencil beam dose algorithm allowed us to simulate a much greater number of treatment
plans, with varying factors, than would have been possible in a practical timeframe using
more accurate dose calculations such as Monte Carlo algorithms. Therefore, we chose speed
over accuracy, but we also expect that our findings would not significantly change by using
a more accurate dose algorithm. Another limitation was that we optimized the particle
fluence for a single reference motion state, e.g., at end-exhale, prior to calculating the beam
tracking offsets for each pencil beam for each motion state. That is, we did not account for
all motion states in the planning of particle numbers, which partially explains some of our
degraded target dose seen even for perfect tracking. These limitations are being addressed
in ongoing studies in our laboratory; however, these limitations did not prevent us from
achieving our objective, which was to evaluate the robustness of target dose coverage to
motion uncertainties for scanned carbon ion beam tracking therapy of moving targets.
Based on our findings, we propose the following future studies. First, we suggest that
appropriate beam-specific margins could be designed to mitigate range errors introduced
by lateral target misalignment, similar to the approach of Park et al. (2012), but also
including motion margins needed to cover the deforming tissue during respiration (Graeff
et al., 2012). For beam tracking of a deforming target, the ideal field margins could be
a “center-of-mass ITV,” which covers any range and positional uncertainty for all motion
states. Second, optimization could be used to further optimize pencil beam fluence in a way
that is optimal for all motion states, which would be beneficial, since, for this 3D-optimized
beam tracking approach, it is unknown prior to treatment in which motion state a pencil
beam will be irradiated.
Strategies to improve robustness have already been developed for both photon therapy (Bortfeld et al., 2008; Unkelbach et al., 2009) and particle therapy (Unkelbach, 2007;
Pflugfelder et al., 2008; Chen et al., 2012; Liu et al., 2012). Many of these strategies incorporated uncertainties in plan optimization to improve probability of tumor control in
the presence of patient setup uncertainty, though, to our knowledge, do not yet explicitly
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address robustness to organ motion for particle therapy. Theoretically, robust 4D optimization could be used to optimize particle numbers that are both optimal for all motion
states and robust to motion uncertainties, likely benefiting patients with thoracic motion
receiving scanned ion beam therapy in the near future.
In summary, we developed a new method to model the impact of motion uncertainties
for scanned ion beam tracking and implemented our work in a 4D research treatment planning system. We quantified the sensitivity of target dose to several uncertainties present in
scanned carbon ion beam tracking for moving tumors using both mathematical phantom
studies and retrospective lung cancer patient studies. Our results provide a better understanding of the importance of each of these uncertainties for beam tracking with scanned
carbon ions.

79

Chapter 4
Predicted Risk of Second Cancer Incidence
in the Breast for Hodgkin Lymphoma
Patients After Carbon Ion Therapy versus
Proton Therapy
4.1

Introduction

Approximately 9000 men and women will be diagnosed with Hodgkin lymphoma (HL)
this year in the USA (i.e., 2013), and nearly 200,000 citizens are currently living with a
history of HL (Howlader et al., 2013). Furthermore, HL is one of the most common cancers
affecting adolescents and young adults (Bleyer et al., 2006). Patients diagnosed with early
stage HL are mainly treated with combined chemotherapy and radiation and can expect
survival higher than 90% at 5 years (Armitage, 2010) and 60-80% at 20 years, with survival
rates decreasing with age at diagnosis (Bleyer et al., 2006). For this population of patients,
side effects of therapy can in some cases be devastating, including second primary cancers,
cardiac toxicity, and infertility (Robison et al., 2002). For example, Dores et al. (2002)
reported a 10.5% absolute excess risk of cancer in the female breast for patients treated
with radiation, mainly using photon mantle fields. Due to their long expected survival after
therapy, HL patients stand to greatly benefit from new treatment strategies that reduce
risks of radiation late effects.
Research in the past decades has focused on reducing radiation dose to healthy tissue
and the overall size of therapy fields. Reducing the radiation field size, e.g., using Involved
Field Radiation Therapy rather than Extended Field Radiation Therapy, can reduce dose
to critical structures near the HL target (Koh et al., 2007). Recently, Chera et al. (2009)
demonstrated in planning studies that a reduction of dose to the breast, lung, and total
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body was possible using proton therapy instead of photon therapy for a sample of HL
patients with localized disease above the hilia. Due to the sharper physical dose gradients
(Weber and Kraft, 2009) and higher relative biological effectiveness (RBE) (Elsässer et
al., 2010), carbon-ion therapy might provide further reductions in dose to normal tissues
compared to proton therapy for some HL patients.
Carbon beams provide an increased relative biological effectiveness (RBE) for cell
sterilization near their Bragg peak where linear energy transfer (LET) is fairly high, i.e.,
tens to hundred of keV/µm. Upstream of the Bragg peak, carbon beams have lower LET
and thus lower RBE than that found near the Bragg peak. Due to this differential RBE
ratio, dose for carbon-ion therapy can be planned to provide equivalent tumor control
to proton therapy but with lower physical dose to healthy tissue upstream of the tumor
(Schardt et al., 2010; Elsässer et al., 2010). However, despite the reduced physical dose, the
biological effectiveness of high LET radiation to induce late effects is much less understood
than that of low LET radiation and could increase risks of second cancer after radiotherapy.
In order to estimate risks of secondary malignant neoplasms after exposure to radiation, many studies rely on epidemiological studies of atomic bomb survivors and follow
up of cancer survivors exposed to photon radiation during the past century. Translation of
these data to useful models that can predict risks of second cancer in partially irradiated
organs for patients receiving modern radiotherapy is challenging. Most epidemiological
data support a linear-no-threshold risk model (NRC, 2006), but Schneider et al. (2005),
along with others, propose that support for a linear-no-threshold model may be an artifact
of the epidemiological studies themselves, which typically only accounted for integral organ
doses and thus may have missed any non-linear correlations between point organ doses and
second cancer risks. Theoretically, healthy cells, susceptible to neoplastic transformation
by radiation, could also be sterilized by radiation, which might lead to a decrease of cancer
risk at very high doses. This is not clearly observed in epidemiological data except for the
thyroid (NRC, 2006), but it is seen clearly in in-vivo experiments, e.g., induction of myeloid
leukemia in mice (Coggle, 1988). Recently, Schneider et al. (2011) developed a risk model
for breast cancer incidence after photon therapy that accounted for the competing processes of radiation breast cell transformation, breast cell inactivation, and cell repopulation
during fractionated radiotherapy. Their model parameters were fit to the epidemiological
study of breast cancer incidence in HL survivors of Travis et al. (2003) and agreed closely
with a linear-no-threshold model for atomic bomb survivor data at lower doses but modeled
a non-linear decrease in risk at higher doses, e.g., higher than 20 Gy.
In order to apply risk models developed for photon radiation exposures to patients
receiving charged particle therapy, a method of calculating RBE for tumor induction by
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Figure 4.1: Example of RBE dependence on LET for carbon ion irradiation for the sterilization of V79 Chinese hamster ovary cells. Note that RBE generally increases with LET
until reaching a peak RBE. After this peak RBE, a further increase in LET leads to a
decrease in RBE, i.e., the “overkill effect.” Curves show the predictions of LEMIV. Figure reproduced from Friedrich et al. (2012), and the experimental data were acquired by
Furusawa et al. (2000).
charged particles is needed. Very little data are available describing cancer incidence in
humans exposed to charged particle radiation. Further, since the exact mechanism of
cancer induction by radiation is not known, it is not possible to assume the same RBE
will hold for different endpoints, e.g., cell sterilization versus tumor induction. Furusawa
et al. (2000) investigated cell sterilization as a function of ion species and LET, reporting
RBEs for cell sterilization by helium, carbon, and neon ions in a range of approximately
1-10, depending on cell line and endpoint and generally increasing with LET until the
overkill effect was reached, i.e., with an RBE maximum at approximately 100-200 keV/µm
for carbon ions (cf. Figure 4.1). Similar findings were reported for cell sterilization by
carbon ions with dependencies on the repair capacity of cell lines (Weyrather et al., 1999).
Given this knowledge, a general increase of RBE versus LET might be expected for cancer
induction after ion irradiation (Fry et al., 1985) and, indeed, an increase in the yield of
chromosomal aberrations with increasing LET per unit dose is seen in vitro for heavy ions,
compared with photons (Durante et al., 2002), but in vitro cell results cannot be directly
used to infer cancer risks in vivo. Also, the saturation effect, i.e., “overkill effect,” that
is typically seen in RBE versus LET studies for the endpoint of cell sterilization may or
may not be expected for the endpoint of tumor induction. Alpen et al. (1993) studied the
RBE for tumorigenesis in the Harderian gland of the mouse for irradiation with hydrogen,
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helium, neon, iron, and niobium ions and reported a linear increase in RBE versus LET
over a large range of 1-1000 keV/µm, with no observed decrease in RBE at high LET.
Furthermore, RBE for ion beams has been shown to not only depend on the ion LET
but also on the ion species (Furusawa et al., 2000; Friedrich et al., 2013a). Despite these
challenges, risk estimations, however coarse, for cancer incidence after exposure to ion
radiation can offer valuable insights and provide new fuel for future research efforts in the
fields of both radiation oncology and space exploration. Indeed, the same difficulties in
estimating RBE for tumor induction by ion irradiation exist for those who try to predict
and minimize cancer risks for astronauts who would be exposed to cosmic rays during
extended space missions (Durante and Cucinotta, 2008; NCRP, 2006; NRC, 2008).
For some HL patients, scanned carbon ion therapy might reduce physical dose to
normal tissues upstream of the target compared with scanned proton therapy. However,
estimation of the risks of secondary malignant neoplasms for these patients is not straightforward and likely depends on complex, competing relations between the RBE for HL tumor
control, RBE for normal tissue tumor induction, and RBE for normal tissue sterilization,
which likely all depend on the radiation particle spectrum and the radiosensitivity of individual tissues. To our knowledge, a study comparing second cancer risk in the breast
for HL patients after carbon ion versus proton radiotherapy has not been reported in the
literature.
The purpose of this study was to determine whether using carbon ion therapy instead
of proton therapy would show a difference in the predicted risk of second cancer incidence
in the breast for female HL patients. To achieve this, we simulated scanned proton and
scanned carbon ion treatment for 6 HL patients using a research treatment planning system for ion radiotherapy. We calculated relative predicted risks of second cancer in the
breast using a linear-no-threshold tumor induction model and a linear-quadratic breast cell
inactivation model. We explicitly modeled RBE values for the ion fields for both breast
tumor induction and cell inactivation. We further investigated the sensitivity of our risk
predictions to uncertainties in our RBE calculations.

4.2

Methods

4.2.1

Patient Sample

We selected patient records for 6 women who had previously received passively scattered proton therapy for HL with stage IIA, IIB, or IIBE diagnoses and disease targets
localized above the diaphragm. These patient records were consecutively sampled based
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on 2 criteria: (1) these women were previously determined by radiation oncologists at
UTMDACC to be valid candidates for proton therapy, (2) disease targets were located
superior to the diaphragm. Many of these supradiaphramatic targets required particle
beams traversing healthy breast tissue and thus were appropriate test cases for radiogenic
second cancer incidence risk in the breast. Data for these patients were collected under a
retrospective research protocol approved by our institutional review board. All protected
health information was removed from the electronic medical record using the methods of
Newhauser et al. (in preparation).
4.2.2

Treatment Planning

Treatment planning for scanned proton therapy and scanned carbon ion therapy was
performed using the TRiP98 TPS (Krämer et al., 2000; Krämer and Scholz, 2000) and the
Local Effect Model Version IV (LEMIV) (Scholz et al., 1997; Elsässer et al., 2010) at GSI.
To review, the principle of the Local Effect Model (LEM) (Scholz et al., 1997) is that,
microscopically, the biological response of DNA to photon and ion irradiation is essentially
the same. However, the dose distributions produced by ion irradiation are highly nonuniform at the microscopic level (e.g., nm to µm scale), and thus macroscopic dose is a
poor indicator of biologic effect after ion irradiation. By using an amorphous track structure
model, one can predict the microscopic distribution of dose from ion irradiation within a
cell nucleus and use that to predict the distribution of “lethal events” (e.g., that would
be produced by an equivalent microscopic dose of photons). By integrating the number of
these lethal events over the cell nucleus, one can compare that ion dose with the photon dose
that would produce an equivalent number of lethal events and, thus, estimate a macroscopic
RBE value for ion irradiation. A more recent extension of that model (LEMIV) (Elsässer
et al., 2010) uses similar theory but goes one step further to predict the number of DNA
double-strand breaks (DSBs) and to score the complexity of DNA damage, i.e., scoring
the number of DSBs that occur within a very small (e.g., 540 nm) distance scale. Multiple
DSBs to the DNA within very small distances are considered more lethal than the same
number of DSBs spread further apart throughout the DNA structure. Similar to the initial
LEM, LEMIV links known photon biological response to predicted ion biological response,
considering the microscopic track structure of ions and the complexity of DNA damage at
a microscopic level. Hence, LEMIV can be used similarly to determine macroscopic RBE
values for use in treatment planning and dose optimization for ion radiotherapy.
For all patients, scanned proton and scanned carbon treatment plans were prepared
according to the following procedure.
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1 Following the methods of Elsässer et al. (2010), RBE tables were computed using
LEMIV for the HL target and the breast. These tables consisted of the RBE values
for carbon and all lighter ions down to hydrogen at various kinetic energies. The
RBE values in these tables specifically represented the RBE values for the case when
a single particle traverses the cell nucleus; these values were used as input to TRiP98
to allow calculation of RBE weighted dose for particle fields with mixed ion species
and kinetic energies and mixed LET (Krämer and Scholz, 2006).
• For the HL target, RBE tables were calculated based on a linear-quadratic model
for sterilization of the HL tumor using α/β of 8 Gy, with α = 0.2 Gy−1 and
β = 0.025 Gy−2 .
• For the breast, RBE tables were calculated for breast cell sterilization α/β of 3
Gy (Yarnold et al., 1995, 2005; Schneider et al., 2011), with α = 0.12 Gy−1 and
β = 0.04 Gy−2 .
2 Computed tomograms (CT) and organ contours from the HL patient records were
loaded into the TPS.
3 Scanned proton and scanned carbon fields were planned to irradiate the clinical target
volume (CTV) using a single anterior-to-posterior beam direction for each patient.
• Pencil beams had focal spot sizes of 12.4 ± 1.7 mm full-width at half-maximum
(FWHM) for protons and 7.0±0.3 mm FWHM for carbon ions, typical of clinical
parameters used at HIT (Heidelberg, Germany).
• Pencil beam Bragg peak coordinates were regularly spaced laterally with 2 mm
between raster spots and isoenergy slices were regularly spaced with approximately 3 mm water-equivalent depth separation.
• A 3-mm ripple filter was used to broaden the carbon Bragg peak along the depth
axis (Weber and Kraft, 1999).
• A lateral margin of 1.1× FWHM of the pencil beams was used to achieve sufficient lateral scatter equilibrium for dose coverage at the lateral target boundary.
A distal margin of 4 mm was used to cover the deepest portion of the target.
4 Particle numbers were optimized for each pencil beam to provide a uniform RBEweighted dose per fraction of 2 Gy (RBE) to the CTV, i.e., that would be delivered
in 18 fractions for 36 Gy (RBE) total. A gradient search minimization was used to
minimize the objective function; the minimizer was stopped once the relative change
in the objective function dropped below 1 × 10−3 .
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5 Both absorbed dose and RBE-weighted dose were calculated in each CT voxel using
the TPS. For voxels in the CTV, the RBE table for HL tumor sterilization was used.
For all other voxels in the patient, the RBE table for breast cell sterilization was used.
6 Dose-averaged LET (i.e., the LET value was weighted by the absorbed dose in averaging) was calculated in each CT voxel for the particle spectra produced by the
proton and carbon fields (Krämer and Scholz, 2006).
For each treatment plan, we used the reference RBE table for breast cell sterilization
with α/β = 3 Gy, as mentioned above. However, we also performed a sensitivity test
by recalculating RBE-weighted dose to the breast using RBE tables with α/β = 1 Gy
and α/β = 5 Gy. Similarly, we recalculated treatment plans using RBE tables for the
HL tumor with α/β ratios of 6, 8, and 10 Gy. Although the exact α/β ratio for HL
tumors is not known (to our knowledge), we estimated a value of 8 Gy based on clinical
experience at UTMDACC and attempted to bracket a range of plausible values from 6-10
Gy. DT , the dose at which the linear-quadratic cell survival curve transitions to a purely
linear curve, was estimated for each α/β ratio using an empirical estimate at GSI, that is
DT = 1.1 × α/β + 4 Gy.
To visualize our treatment plans, we prepared dose colorwash 2D cuts from the 3D
dose distributions and overlaid these on corresponding CT slices along with the CTV and
organ contours. We prepared histograms of RBES -weighted dose to the breast. We plotted
dose-averaged LET colorwash maps overlaying the organ contours. To visualize the entire
distribution of dose-averaged LET in the breast for the carbon and proton treatment plans
simultaneously for all patients, we plotted histograms of dose-averaged LET in all breast
voxels from all patients. Further, we plotted RBES colormaps and histograms of RBET in
breast to better understand the spectra of RBE predicted for these patients.
4.2.3

Calculation of Relative Risks of Secondary Malignant Neoplasms

In order to minimize the number of variables that contribute to uncertainty in risk
prediction for secondary malignant neoplasms, we considered only the ratio of predicted
risks of breast cancer incidence for the carbon versus proton treatment plans. Following
the methods of Newhauser et al. (2009) and Fontenot et al. (2010), we calculated the ratio
of predicted breast cancer incidence risk (Rc /Rp ) for each patient comparing proton (p)
and carbon (c) therapy as
hTc · Sc i
Rc
=
,
(4.1)
Rp
hTp · Sp i
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where T is the probability of tumor induction and S is the surviving fraction of breast cells.
We calculated T and S at points on a 3D grid with 8-mm spacing throughout the patient.
The brackets indicate that we averaged the point calculations of T · S for all points in the
breast for carbon and proton plans before taking the ratio of risk. For the tumor induction
term, we used a linear-non-threshold model with a modification to account for the variable
RBE of protons and carbon ions for carcinogenesis.
T = µ · D · RBET ,

(4.2)

where µ is the slope of risk per absorbed dose D that is typically seen in linear-non-threshold
photon risk models. However, in this study, µ in the numerator and the denominator
cancelled and thus had no effect on our ratio of risk (Rc /Rp ). To estimate the RBE for ions
for tumor induction (RBET ), we developed a linear model of RBE versus LET, based on
our interpretation of the literature (Alpen et al., 1993; Hawkins, 1998; Carabe et al., 2012;
NCRP, 2006).
RBET = 1 + k · LET,
(4.3)
where k depends on ion species. A precondition for this equation to be valid is that the
LET is sufficiently small that saturation effects, such as the “overkill effect,” do not play a
role. We assumed a fixed relation between proton and carbon (kp = κ · kc ) and estimated a
plausible range for kc as (0.01 < kc < 0.09) µm/keV, corresponding to an RBE maximum of
2-10 for carbon at 100 keV/µm, inferred from cell survival RBE data reported by Furusawa
et al. (2000). We estimated κ to fall in the plausible range of (1 < κ < 5) (Schardt et al.,
2010; Friedrich et al., 2013a). Assuming that only surviving breast cells pose risk for tumor
induction, we used a linear-quadratic survival calculation (Hall and Giaccia, 2006)



S = exp −n α · d · RBES + β(d · RBES )2 ,

(4.4)

where n is the number of fractions (i.e., n = 18), d is the absorbed dose per fraction to a
point in the breast. RBES was calculated using the treatment planning system, and α and
β values for breast cell sterilization were those described in Section 4.2.2.
To test the sensitivity of our computed risk ratios to uncertainties in our risk model
parameters, we plotted (Rc /Rp ) for all patients for the range of kc and κ discussed above and
with varying α/β ratios for breast cell sterilization of 1, 3, and 5 Gy and with varying α/β
ratios for HL tumor sterilization of 6, 8, and 10 Gy. In addition, we prepared histograms of
RBET for all breast voxels for the proton and carbon treatment plans for a reference case
with kc = 0.05 µm/keV and κ = 3 to better illustrate the distribution of RBET predicted
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by our model.
4.2.4

Statistical Analysis of Risks

For our risk comparisons and range of sensitivity testing, we performed a two-sided
Sign Test using MATLAB (MathWorks, Natick, Massachusetts). That is, we tested the
null hypothesis Ho that proton therapy and carbon-ion therapy provided equal risk of
second cancer incidence in the breast for the 6 HL patients. This could be expressed
mathematically as
Ho : ∆ = 0,
(4.5)
and
H1 : ∆ 6= 0,
where


∆ = median

Rc
Rp




− 1 , i = 1, 2, 3, 4, 5, 6.

(4.6)

(4.7)

i

For each of the sensitivity tests described in Section 4.2.3, we analyzed (Rc /Rp ) for all
patients (i) and computed a p-value. If the p-value was less than 0.05, we rejected the null
hypothesis and accepted the alternative hypothesis H1 . When we accepted the alternative
hypothesis, we interpreted findings of ∆ < 0 to imply that carbon-ion therapy tended
to result in a lower risk of second cancer incidence in the breast than proton therapy.
Conversely, we interpreted findings of ∆ > 0 to imply that carbon-ion therapy tended to
result in a higher risk of second cancer incidence in the breast than proton therapy.

4.3

Results

4.3.1

Treatment Plans and RBE-Weighted Dose Distributions

A comparison of proton and carbon ion treatment plans are shown in Figure 4.2 for
HL Patient #1. Compared to the proton plan, the carbon plan shows higher conformity of
dose to the CTV with more rapid falloff of the high dose region both laterally and distally
to the CTV. A lower RBE-weighted dose (i.e., RBES -weighted dose) is seen in the left
breast for carbon versus proton, both in the lateral penumbra and in the primary beam
entrance path. A lower RBE-weighted dose is also seen in the right breast, due to the
sharper lateral penumbra of the carbon beam. Interestingly, the carbon treatment plan
shows a halo-shaped region of overdose in healthy tissue near the border of the CTV on
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Figure 4.2: Scanned proton (left) and scanned carbon ion (right) treatment plans for
HL Patient #1. RBE-weighted dose colorwash is shown overlaying axial (top), coronal
(middle), and sagittal (bottom) CT slices. Contours (white lines) are shown for the CTV
(T), right breast (RB), left breast (LB), lung (L), esophagus (E), spinal cord (C), and heart
(H). RBE-weighted dose was calculated using one RBE table for HL tumor sterilization
inside the CTV (α/β = 8 Gy) and another RBE table for breast cell sterilization for all
tissues outside the CTV (α/β = 3 Gy). The prescribed CTV RBE-weighted dose was 36
Gy (RBE). Note the lower RBE-weighted dose, i.e., RBES , in the left breast seen for the
carbon plan compared with the proton plan.
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all sides, due to the different radiosensitivity of the HL tumor and the surrounding normal
tissue. It should be noted again that the RBE-weighted doses to all normal tissues were
calculated using the RBE table for breast cell sterilization (α/β = 3 Gy). In addition, a
non-zero exit dose is seen for carbon that extends far beyond the distal CTV boundary,
due to fragmentation of the carbon projectiles.
Figures 4.3 and 4.4 show axial views of the proton and carbon treatment plans for
HL Patients #2 - #6. Differences between the carbon and proton plans for all patients
were similar to those seen for Patient #1, namely:
• Carbon plans show a sharper lateral penumbra and higher conformity of therapeutic
dose to the CTV than proton plans.
• Carbon plans show a faster distal falloff of dose than proton plans except for the
fragmentation tail, which extends low dose far beyond the distal target boundary.
• Carbon plans show a lower RBE-weighted dose to the breast, i.e., RBES -weighted
dose, than proton plans for all patients.
• Carbon plans introduce a halo-shaped region of overdose in normal tissue near the
CTV boundary, particularly on the downstream side of the target.
Figure 4.5 shows the distribution of RBES -weighted doses seen in the breast for all 6
HL patients as a histogram where all breast voxels for all patients have been combined in
a single plot. The overall shapes of these differential RBES -weighted dose histograms were
similar for the proton and carbon plans.
4.3.2

LET Distributions

To complement the treatment planning views presented above, Figure 4.6 shows 2D
colorwash plots of the dose-averaged LET for proton and carbon ion therapy plans for HL
Patient #1. As the ion beams enter the tissue, the LET is generally seen to increase with
depth in tissue, as the ions lose kinetic energy. The highest LET is seen at the distal
field boundary, where the deepest Bragg peaks are positioned. Carbon ion LET values are
roughly 10 times higher than proton LET values, and for both ion species, the LET is lower
in the breast than in the CTV. Entire distributions of dose-averaged LET for all breast
voxels for all patients are shown as histograms in Figure 4.7 for the proton and carbon
plans. Importantly, values of dose-averaged LET in the breast for both the proton and
carbon ion plans for all patients were lower than typical values of LET where saturation
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Figure 4.3: Axial view of scanned proton and scanned carbon ion treatment plans for
HL Patients #2, #3, and #4. Patient number is indicated in the top left of each image.
Contours (white lines) are shown for the CTV (T), right breast (RB), left breast (LB),
lung (L), esophagus (E), spinal cord (C), and heart (H). RBE-weighted dose was calculated
using one RBE table for HL tumor sterilization inside the CTV (α/β = 8 Gy) and another
RBE table for breast cell sterilization for all tissues outside the CTV (α/β = 3 Gy). The
prescribed CTV dose was 36 Gy (RBE).
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Figure 4.4: Axial view of scanned proton and scanned carbon ion treatment plans for HL
Patients #5 and #6. Patient number is indicated in the top left of each image. Contours
(white lines) are shown for the CTV (T), right breast (RB), left breast (LB), lung (L),
esophagus (E), spinal cord (C), and heart (H). RBE-weighted dose was calculated using
one RBE table for HL tumor sterilization inside the CTV (α/β = 8 Gy) and another RBE
table for breast cell sterilization was used for all tissues outside the CTV (α/β = 3 Gy).
The prescribed CTV dose was 36 Gy (RBE).
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Figure 4.5: Histogram of RBES -weighted dose in breast voxels for scanned proton (top)
and scanned carbon ion (bottom) treatment plans for all 6 patients.
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Figure 4.6: Distributions of dose-averaged LET shown for the scanned proton (left) and
scanned carbon ion (right) treatment plans for HL Patient #1. Organ contours (white contours) are shown for the CTV (T), right breast (RB), left breast (LB), lung (L), esophagus
(E), spinal cord (C), and heart (H). For both plans, higher LET is seen near the distal edge
of the CTV but comparably low LET is seen in the breast.
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Figure 4.7: Histogram of dose-averaged LET in breast voxels for scanned proton (top) and
scanned carbon ion (bottom) treatment plans for all 6 patients.
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effects in RBES are known to occur, namely near 20-30 keV/µm for protons and near
100-200 keV/µm for carbon ions (cf. Figures 1.4 and 4.1).
4.3.3

RBE Distributions

An illustration of the predicted RBES values for cell sterilization, calculated by
LEMIV, is shown for HL Patient #1 in Figure 4.8 for the reference case with breast cell
α/β = 3 Gy. Similar to the distributions of LET, the highest values of RBES , up to approximately 6 for both proton and carbon plans, were seen near the distal field boundary.
Carbon plans showed a generally higher RBES in the target with a more gradual increase
in RBES as the carbon ions approach the distal target edge compared to proton plans.
Predictions of our model for RBET versus LET, i.e., RBE values for tumor induction, are
shown in Figure 4.9. Based on this model, an example of predicted RBET for voxels in
the breast for all 6 patients for proton and carbon plans is shown in Figure 4.10. For our
reference case of kc = 0.05 µm/keV and κ = 3, RBET values are seen ranging from 1 to 3.3
for proton dose to the breast and from 1 to 5.3 for carbon dose to the breast.
4.3.4

Relative Risks of Second Cancer Incidence in Breast

The predicted ratios of risk (Rc /Rp ) of breast cancer incidence for the 6 HL patients
receiving scanned carbon ion versus scanned proton therapy are shown in Figures 4.11,
4.12, and 4.13, with α/β ratios for breast cell sterilization of 1, 3, and 5 Gy, respectively.
For a breast α/β of 1 Gy, the mean ratio of risk for all patients, all kc , and all κ was
(Rc /Rp ) = 0.50 ± 0.24. For a breast α/β of 3 Gy, the mean ratio of risk for all patients, all
kc , and all κ was (Rc /Rp ) = 0.77 ± 0.35. For a breast α/β of 5 Gy, the mean ratio of risk
for all patients, all kc , and all κ was (Rc /Rp ) = 0.90 ± 0.40. Mean ratios of risk (Rc /Rp )
for the 6 patients and results of our statistical analysis are presented in Table 4.1 for all
variations of breast α/β, kc , and κ for HL α/β of 8 Gy. For our reference case with breast
α/β = 3 Gy, HL tumor α/β = 8 Gy, kc = 0.05 µm/keV, and κ = 3, we did not find a
significant difference in the risk of second cancer incidence in the breast using carbon-ion
therapy instead of proton therapy for our sample of HL patients. However, some significant
differences were found for some conditions examined in our sensitivity testing (cf. Table
4.1). First, we found that a lower breast α/β led to a lower predicted ratio of risk (Rc /Rp ).
Second, we found a higher kc led to a higher ratio of (Rc /Rp ). Third, we found that a
higher κ led to a lower ratio of (Rc /Rp ). We found the exact α/β ratio for the HL tumor
to have minimal impact on our results for α/β of 6-10 Gy (cf. Appendix B).
Overall, these findings demonstrated that our predicted ratio of risk (Rc /Rp ) was
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Figure 4.8: Distributions of RBES calculated with LEMIV shown for the scanned proton
(left) and scanned carbon ion (right) treatment plans for HL Patient #1. These values
correspond to the RBES -weighted dose distributions shown in Figure 4.2. In these calculations, α/β was 8 Gy for the HL CTV and 3 Gy for the breast and all other tissue. Organ
contours (white contours) are shown for the CTV (T), right breast (RB), left breast (LB),
lung (L), esophagus (E), spinal cord (C), and heart (H). For both plans, higher RBE is
seen near the distal edge of the CTV, where the dose-averaged LET was highest (cf. Figure
4.6).
97

��= 5

kC =

��= 3

m/k
09 �

eV

0.

��= 1
��= 5
��= 3
��= 1

kC = 0.01 �m/keV

Figure 4.9: RBET versus LET model predictions (cf. Equation 4.3) shown over the range of
parameters used in this study, with kc = 0.01 µm/keV (black lines) and 0.09 µm/keV (red
lines) and κ = 1, 3, and 5. The solid lines represent the RBET for carbon irradiations and
the dashed lines, which stop at 30 keV/µm, represent the RBET for proton irradiations.
If κ = 1, then kp = kc . Model predictions for kc = 0.05 µm/keV are not shown here but
appeared similar in shape.
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Figure 4.10: Histograms of predicted RBET for tumor induction in breast voxels for proton
plans (top) and carbon ion plans (bottom) for all 6 patients for our reference case with
kc = 0.05 µm/keV and κ = 3 (cf. Equation 4.3).
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Figure 4.11: Predicted ratio of risk (Rc /Rp ) for breast cancer incidence for the 6 HL patients
receiving scanned carbon versus scanned proton therapy when α/β = 1 Gy for breast cell
sterilization and α/β = 8 Gy for HL tumor sterilization. For each patient, risk ratios are
shown for kc values of 0.01 µm/keV (squares), 0.05 µm/keV (circles), and 0.09 µm/keV
(triangles), i.e., corresponding to peak RBET values for carbon of 2, 6, and 10 at 100
keV/µm, respectively. For each kc , we also calculated risk ratios with variable κ of 1, 3,
and 5. Within each cluster of like kc values, an increasing ratio of risk was found with
decreasing κ.
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Figure 4.12: Predicted ratio of risk (Rc /Rp ) for breast cancer incidence for the 6 HL patients
receiving scanned carbon versus scanned proton therapy when α/β = 3 Gy for breast cell
sterilization and α/β = 8 Gy for HL tumor sterilization. For each patient, risk ratios are
shown for kc values of 0.01 µm/keV (squares), 0.05 µm/keV (circles), and 0.09 µm/keV
(triangles), i.e., corresponding to peak RBET values for carbon of 2, 6, and 10 at 100
keV/µm, respectively. For each kc , we also calculated risk ratios with variable κ of 1, 3,
and 5. Within each cluster of like kc values, an increasing ratio of risk was found with
decreasing κ.
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Figure 4.13: Predicted ratio of risk (Rc /Rp ) for breast cancer incidence for the 6 HL patients
receiving scanned carbon versus scanned proton therapy when α/β = 5 Gy for breast cell
sterilization and α/β = 8 Gy for HL tumor sterilization. For each patient, risk ratios are
shown for kc values of 0.01 µm/keV (squares), 0.05 µm/keV (circles), and 0.09 µm/keV
(triangles), i.e., corresponding to peak RBET values for carbon of 2, 6, and 10 at 100
keV/µm, respectively. For each kc , we also calculated risk ratios with variable κ of 1, 3,
and 5. Within each cluster of like kc values, an increasing ratio of risk was found with
decreasing κ.
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Table 4.1: Mean ratios of predicted risk < Rc /Rp > (averaged over 6 patients) and significance (p-value) for second cancer incidence in breast for HL patients over the interval
of biological parameters varied in our sensitivity testing (cf. Section 4.2.3) with α/β for
HL tumor sterilization of 8 Gy. ∆ was used for our Sign Test (cf. Equation 4.7). p-values
greater than 0.05 were considered insignificant (shown in red).
Breast α/β (Gy) kc (µm/keV) κ
1

0.01

0.05

0.09

3

0.01

0.05

0.09

5

0.01

0.05

0.09

1
3
5
1
3
5
1
3
5
1
3
5
1
3
5
1
3
5
1
3
5
1
3
5
1
3
5
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< Rc /Rp >

∆

0.35
0.34
0.33
0.56
0.51
0.46
0.75
0.64
0.56
0.54
0.53
0.51
0.87
0.79
0.72
1.17
0.99
0.86
0.62
0.61
0.59
1.00
0.91
0.83
1.35
1.15
1.00

-0.69
-0.69
-0.70
-0.49
-0.54
-0.58
-0.30
-0.42
-0.50
-0.51
-0.52
-0.53
-0.19
-0.27
-0.34
0.10
-0.08
-0.20
-0.41
-0.42
-0.44
-0.03
-0.13
-0.21
0.31
0.10
-0.05

p-value
0.03
0.03
0.03
0.03
0.03
0.03
0.69
0.22
0.03
0.03
0.03
0.03
0.69
0.69
0.22
0.69
0.69
0.69
0.03
0.03
0.03
0.69
0.69
0.69
0.22
0.69
0.69

highly dependent on the exact value of biological parameters used in our risk model. While
carbon-ion therapy showed a lower predicted risk of second cancer incidence in breast
compared to proton therapy for most of our sensitivity testing, the large uncertainties
in biological parameters prevented us from rejecting the null hypothesis (Ho ) that proton
therapy and carbon-ion therapy provided equal risk of second cancer incidence in the breast
for HL patients.

4.4

Discussion

In summary, we investigated whether using carbon ion therapy instead of proton
therapy would show a difference in the predicted risk of second cancer incidence in the breast
for female HL patients. We simulated proton and carbon-ion therapy for 6 HL patients and
modeled the ratio of risk for breast cancer incidence after therapy, considering the biological
effectiveness of ion beams. We found that the predicted risk of second cancer incidence in
the breast after carbon ion therapy versus proton therapy was highly dependent on the
RBE for tumor induction and highly sensitive to the α/β ratio for breast cell sterilization.
(Rc /Rp ) decreased with decreasing breast cell α/β. We found risk predictions to be only
minimally sensitive to the α/β ratio for sterilization of the HL tumor (see Appendix B).
For the estimated range of RBET studied in this work and for a reference α/β ratio of 3 Gy
for breast cell sterilization, we did not find a significant difference in the predicted risk of
second cancer incidence in the breast using carbon ion therapy instead of proton therapy.
(Rc /Rp ) was 0.77 ± 0.35. However, our findings support that carbon ion therapy might
be beneficial to decrease risks of radiogenic second cancers for tissues with very low α/β
ratios, e.g., less than 3 Gy.
Due to the large biological uncertainties present, it is difficult to draw strong conclusions from this study. Nonetheless, our findings indicate an important trend, and our
interval of calculated risk ratios suggest that it could be better to use carbon ion therapy
for tissues with low α/β and better to use protons for tissues with high α/β with respect
to carcinogenesis. We interpret this finding to mean that RBE for cell sterilization by
carbon irradiation was higher for low α/β and, thus, the sterilization of cells decreased the
risk of tumor induction by carbon at low α/β for the breast. This finding is theoretically
consistent with the analysis of Friedrich et al. (2013b), who reported an inverse relation
between RBE and α/β at low doses. Perhaps one of the greatest strengths of this work is
that we bring some questions to light that must be answered before strong clinical decisions
can be made. Our findings remind us that continued investigations of the RBE for tumor
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induction by ion irradiation at various LET ranges are in dire need. These investigations
would not only benefit the cancer patients undergoing radiotherapy but also could benefit
manned space exploration programs (Durante and Cucinotta, 2008; NCRP, 2006). Although we hesitate to draw strong conclusions, one clinical implication of this study could
be that, since carbon-ion therapy does not appear to offer a significant ability to reduce
breast cancer risk compared with proton therapy, carbon-ion therapy might not be needed
for HL patients. If true, that might benefit patients and taxpayers financially since proton
therapy is generally less expensive than carbon-ion therapy to deliver. Whether carbon-ion
therapy might reduce the risk of other side effects for HL patients compared to proton therapy, e.g., lung cancer risk or cardiac toxicity risk, remains to be investigated. If no strong
ability to reduce risks of side effects is found for carbon versus proton for HL patients,
proton therapy might also be safer to deliver than carbon ion therapy, since the impact of
some uncertainties in RBE modeling are dampened by the lower LET and greater range
straggling of protons compared to carbon ions. That is, mistakes in RBE modeling might
be washed out more in proton therapy than carbon ion therapy.
Reports from the literature caution that “the data for induction of cancer in humans
by protons or heavy ions is insufficient for the estimation of [cancer] risks” (NCRP, 2006).
However, much stands to be gained by carrying out this research, and scientists in both radiation oncology (Newhauser et al., 2009) and space exploration fields (NRC, 2008) continue
to coarsely estimate these risks, despite their large uncertainties. Furthermore, recent studies developed by Fontenot et al. (2010), among others, demonstrate that sensitivity testing
can be included in these risk estimations in a way that provides a level of confidence in such
findings. We used similar methods in this work, though we specifically modeled the RBE
for tumor induction as a function of the LET for proton beams and carbon ion beams in
patient tissue. In this work, our RBE versus LET model had a maximum RBE value of 10
for carbon at 100 keV/µm. That maximum RBE value was approximately consistent with
RBE values determined by Furusawa et al. (2000) for sterilization of Chinese hamster ovary
cells. Additionally, Dicello et al. (2004) reported RBEs of 10 or less for tumor induction by
iron ions in rat mammary. Although the ion species was different, their finding supports
our interval of sensitivity testing.
One strength of this work was that we performed the first in-silico comparison of
carbon ion therapy versus proton therapy for HL patients reported worldwide. Another
strength was that we calculated risks of second cancer incidence in the breast on a voxelized basis for ion therapy considering (1) absorbed dose, (2) dose-averaged LET, (3) cell
sterilization, and (4) variable RBE. In addition, we performed a broad range of sensitivity testing to understand the robustness of our risk predictions to biological uncertainties.
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Another strength was that we simulated therapy without using beam margins to account
for patient setup. Thus, our risk findings reflect some of the most fundamental differences
between carbon-ion therapy and proton therapy. Although treatment without large setup
margins might be possible in the future, e.g., using real-time magnetic resonance imaging
to identify tumor position and guide particle therapy, setup margins are routinely used
now. Therefore, we also simulated treatment and calculated ratios of risk with 5-mm radial beam margins added to the proton and carbon-ion treatment plans. Those data are
presented in Appendix B. We found a small (approximately 4%) increase in the ratio of risk
of breast cancer incidence for carbon-ion versus proton therapy when 5-mm radial margins
were included, compared to plans without setup margins.
This study had several limitations. First, we only analyzed the breast as an organ
at risk. Other radiation side-effects, such as risks of cardiac toxicity, lung fibrosis, and
esophageal fibrosis should be addressed in future studies and might affect the ultimate
conclusion as to whether carbon or proton therapy is a better choice for HL patients. In
fact, all RBES -weighted doses computed outside the HL targets were calculated using RBE
tables with α/β of 1, 3, and 5 Gy, and, therefore, our RBE-weighted dose values could
be used for estimating risks to other organs having an α/β ratio of in that interval, such
as the lung and heart. Second, the true RBET of carbon ions at 100 keV/µm for breast
tumor induction might be higher than our maximum sampled value of 10. In that case, our
predicted risk ratios would likely become more dependent on the exact relation between
kc and kp . Third, we used a linear RBE versus LET model for tumor induction, known
to fail at high LET. However, in this work we only applied this model to relatively low
LET values found in the breast in the beam entrance path. Further work is required to use
this model for treatment plans that might deliver higher LET distributions to the breast,
e.g., for a lateral beam to complement the anterior-to-posterior beam. Fourth, we only
calculated 3D dose and ignored the effects of patient respiration on accumulated 4D dose.
Interplay effects might occur during scanned ion delivery, and motion mitigation strategies
such as those described in Chapters 2 and 3 might be required to ensure accurate dose
delivery. Some of these limitations are currently being addressed in ongoing studies in our
laboratory, but they did not prevent us from achieving our objective, that was to determine
whether using carbon ion therapy instead of proton therapy would show a difference in the
predicted risk of second cancer incidence in the breast for female HL patients
Based on the findings of our study, we propose the following future studies. First,
we propose to reanalyze treatment plans, dose, and LET distributions calculated in this
study using risk models for other organs at risk, e.g., lung, heart, and esophagus, to better
understand risks of side-effects in organs other than the breast. Second, a study focused
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on organ motion and 4D dose calculation might reveal whether motion strategies, e.g.,
4D-optimized beam tracking, might be beneficial for this HL patient population.
In conclusion, we completed a simulation study comparing predicted risks of second
cancer incidence in the breast for HL patients receiving carbon ion therapy versus proton
therapy. We explicitly modeled the biological effectiveness of the ion fields to induce the
competing processes of breast tumor induction and breast cell inactivation. Ultimately, we
did not find a significant difference in the predicted risks of second cancer incidence in the
breast for female HL patients using carbon ion therapy instead of proton therapy for our
reference case. Rather, we found relative risk predictions to depend heavily on both the
α/β ratio for breast cell sterilization and the exact relation between ion LET and the RBE
for tumorigenesis.
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Chapter 5
Conclusion
In conclusion, we sought to test the hypothesis that using 4D-optimized carbon-ion therapy
would reduce the predicted risk of radiation induced second cancers in the breast for female
Hodgkin lymphoma patients while preserving tumor control compared with proton therapy.
To test our hypothesis we completed 3 specific aims.
Specific Aims
1 Determine whether 4D-optimized carbon tracking therapy can reduce dose to volumes outside a moving target while maintaining adequate target dose coverage. We
developed a new scanned ion beam tracking approach using 4D optimization. We
performed water phantom studies and patient studies using computer simulations to
compare dose distributions for moving targets and avoidance volumes for 4D versus
3D-optimized carbon tracking. In addition, we demonstrated the feasibility of our
4D-optimized carbon tracking approach in an experiment using a moving phantom
and a scanned carbon ion beam.
2 Quantify the impact of uncertainties in patient respiratory motion on dose distributions in moving targets for scanned carbon ion beam tracking. We simulated dose
for scanned carbon ion beam tracking using mathematical phantoms and lung cancer
patient 4DCTs. We tested the sensitivity of dose distributions in the target to various systematic and random errors that are characteristic for lung motion and for the
scanned carbon tracking system at GSI. We also investigated the effects of interfractional changes in organ motion on target dose coverage for the lung cancer patients
by simulating treatment on multi-week 4DCTs.
3 Determine whether using carbon-ion therapy instead of proton therapy reduces the
predicted risk of second cancer incidence in the breast for a sample of Hodgkin lym-
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phoma patients. We simulated scanned proton and scanned carbon ion treatment
for 6 HL patients using a research treatment planning system for ion radiotherapy.
We calculated relative predicted risks of second cancer in the breast using a linearnon-threshold tumor induction model and a linear-quadratic breast cell inactivation
model. In addition, we explicitly modeled RBE for the ion fields for both breast
tumor induction and cell inactivation.
With respect to our central hypothesis, we did not find a conclusive difference in
the predicted risk of radiation induced second cancers in the breast for HL patients using
carbon-ion therapy instead of proton therapy. However, we did find that 4D-optimized
scanned ion beam tracking therapy can reduce dose to avoidance volumes near moving
targets, compared to 3D-optimized scanned ion beam tracking therapy, and can be delivered
with a dedicated 4D treatment control system.
Summary of Major Findings
• 4D-optimized scanned ion beam tracking therapy can reduce dose to volumes near
a moving target and improve target dose homogeneity for targets in heterogeneous
tissue, compared to 3D-optimized scanned ion beam tracking.
• Delivery of 4D-optimized scanned carbon ion beam tracking is technically feasible
using the GSI synchrotron or its equivalent.
• 3D-optimized scanned carbon ion beam tracking is sensitive to a number of motion
uncertainties that negatively impact target dose coverage.
• For HL patients, we did not find a significant difference in the predicted risk of
second cancer incidence in breast using carbon-ion therapy instead of proton therapy
but discovered trends in predicted risks depending on the exact biological sensitivities
of breast tissue to ion irradiation.
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Friedrich T., Scholz U., Elsässer T., Durante M., and Scholz M. Calculation of the biological
effects of ion beams based on the microscopic spatial damage distribution pattern. Int.
J. Radiat. Biol., 88(1-2):103–7, 2012.
Friedrich T., Durante M., and Scholz M. Particle species dependence of cell survival rbe:
Evident and not negligible. Acta Oncol., 52(3):589–603, 2013a.
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Schardt D., Elsässer T., and Schulz-Ertner D. Heavy-ion tumor therapy: Physical and
radiobiological benefits. Rev. Mod. Phys., 82(1):383–425, 2010.
Schneider U., Zwahlen D., Ross D., and Kaser-Hotz B. Estimation of radiation-induced
cancer from three-dimensional dose distributions: Concept of organ equivalent dose. Int.
J. Radiat. Oncol., 61(5):1510–5, 2005.
Schneider U., Sumila M., Robotka J., Gruber G., Mack A., and Besserer J. Dose-response
relationship for breast cancer induction at radiotherapy dose. Radiat. Oncol., 6:67, 2011.
Schneider W., Bortfeld T., and Schlegel W. Correlation between ct numbers and tissue
parameters needed for monte carlo simulations of clinical dose distributions. Phys. Med.
116

Biol., 45(2):459–78, 2000.
Scholz M. Effects of ion radiation on cells and tissues. Adv. Polym. Sci., 62:96–155, 2003.
Scholz M., Kellerer A. M., Kraft-Weyrather W., and Kraft G. Computation of cell survival
in heavy ion beams for therapy - the model and its approximation. Radiat. Environ.
Bioph., 36(1):59–66, 1997.
Schulz-Ertner D., Nikoghosyan A., Thilmann C., Haberer T., Jäkel O., Karger C., Kraft G.,
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Appendix A: Additional Results for Beam
Tracking Robustness Study
Results from the robustness studies in Chapter 3 that were not presented in the text are
included here.
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Phantom #1
Phantom #2
Phantom #3
Phantom #4

Figure A.1: Robustness of target dose coverage to random errors in tracking x-coordinates
shown for the 4 phantoms. Target dose coverage V95 (top right) and dose homogeneity
D5 − D95 (bottom right) are seen to degrade when random errors are added with σx > 0.5
mm.
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Phantom #1
Phantom #2
Phantom #3
Phantom #4

Figure A.2: Robustness of target dose coverage to random errors in tracking y-coordinates
shown for the 4 phantoms. Target dose coverage V95 (top right) and dose homogeneity
D5 − D95 (bottom right) are seen to degrade when random errors are added with σy > 0.5
mm.

Phantom #1
Phantom #2
Phantom #3
Phantom #4

Figure A.3: Robustness of target dose coverage to random errors in tracking z-coordinates
shown for the 4 phantoms. Minimal changes in target dose coverage are seen.
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Figure A.4: Robustness of target dose coverage to random errors in tracking x-, y-, and
z-coordinates shown for the 4 phantoms. Target dose coverage V95 (top right) and dose
homogeneity D5 − D95 (bottom right) are seen to degrade when random errors are added
with σ > 0.5 mm. Similarly, the volume of overdose V107 (bottom left) increases when
σ > 0.5 mm.
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Phantom #1
Phantom #2
Phantom #3
Phantom #4

Figure A.5: Robustness of target dose coverage to systematic errors in tracking xcoordinates shown for the 4 phantoms. Note that the impact of x-axis offset is greatest
for Phantom #4 (orange markers), since even small x-axis offset may also introduce more
complicated range shifts due to the air cavity upstream of the target. A similar effect is
seen for Phantom #3 (blue markers), which contained a rib heterogeneity upstream of the
target. Phantoms #1 and #2 are homogeneous and exhibit negligible dependence on x-axis
shifts until the shifts are large enough at 3 to 4 mm so that the target is relatively close
to the lateral field edge boundary where multiple Coulomb scatter equilibrium conditions
begin to deteriorate. Increase in overdose (V107 ) with x-offset is also seen for Phantoms #3
and #4.
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Figure A.6: Robustness of target dose coverage to systematic errors in tracking ycoordinates shown for the 4 phantoms. Very little effect on target dose coverage is seen
until the y-offsets are greater than 2 mm.

Phantom #1
Phantom #2
Phantom #3
Phantom #4

Figure A.7: Robustness of target dose coverage to systematic errors in tracking zcoordinates shown for the 4 phantoms. Very little effect on target dose coverage is seen
until the z-offsets are greater than 2 mm.
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Figure A.8: Robustness of target dose coverage to random errors in tracking x-coordinates
shown for Lung Patient #1. Minimal effects are seen for this interval of simulated errors.

Figure A.9: Robustness of target dose coverage to random errors in tracking y-coordinates
shown for Lung Patient #1. Minimal effects are seen for this interval of simulated errors.
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Figure A.10: Robustness of target dose coverage to random errors in tracking z-coordinates
shown for Lung Patient #1. Slight effects on target dose coverage are seen for this interval
of simulated errors.

Figure A.11: Robustness of target dose coverage to random errors in tracking x-, y-, and
z-coordinates shown for Lung Patient #1. Slight effects on target dose coverage are seen
for σ ≥ 0.5 mm.
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Figure A.12: Robustness of target dose coverage to systematic errors in tracking xcoordinates shown for Lung Patient #1. A decrease in V95 is seen with increasing magnitude
of x-offset.

Figure A.13: Robustness of target dose coverage to systematic errors in tracking ycoordinates shown for Lung Patient #1. Very little effect on target dose coverage is seen
until the z-offsets are greater than 2 mm.
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Figure A.14: Robustness of target dose coverage to systematic errors in tracking zcoordinates shown for Lung Patient #1. A gradual decrease in V95 is seen with increasing
magnitude of z-offset.
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Table A.1: Robustness of 4D-optimized beam tracking to interfractional changes in organ
motion for Lung Patient #1. Dose and volume statistics compare treatment simulated on
an initial planning 4DCT (i.e., Week 0) and a follow-up 4DCT acquired one week later (i.e.,
Week 1). Target dose coverage V95 degraded after one week by 11% but was better than that
of 3D-optimized beam tracking at both Week 0 and Week 1 (cf. Figure 3.15). Maximum
dose to the heart increased by 11% but remained lower than that for 3D-optimized beam
tracking (see Table 2.1). Data reported as percentages. Difference calculated by subtracting
the week 0 values from the week 1 values.
Volume

Metric

CTV

D̄
σD
Dmin
Dmax
V95
V107
D5 − D95
D̄
Dmax

Heart

Week 0

Week 1

Difference (%)

99.9
0.9
54.2
109.7
99.9
0.1
1.8
7.1
104.0

97.8
6.2
29.0
108.4
88.9
0.1
13.4
11.8
114.8

-2
+5
-25
-1
-11
0
+12
+5
+11
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Appendix B: Additional Results for Second
Cancer Risk Study
Results from the second cancer risk study in Chapter 4 that were not presented in the text
are included here.
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HL Tumor ��� = 6 Gy
Breast ��� = 1 Gy
(Rc/Rp) = 0.50 ± 0.24

HL Tumor ��� = 10 Gy
Breast ��� = 1 Gy
(Rc/Rp) = 0.48 ± 0.23

HL Tumor ��� = 6 Gy
Breast ��� = 3 Gy
(Rc/Rp) = 0.79 ± 0.36

HL Tumor ��� = 10 Gy
Breast ��� = 3 Gy
(Rc/Rp) = 0.76 ± 0.34

HL Tumor ��� = 6 Gy
Breast ��� = 5 Gy
(Rc/Rp) = 0.91 ± 0.40

HL Tumor ��� = 10 Gy
Breast ��� = 5 Gy
(Rc/Rp) = 0.88 ± 0.39

Figure B.1: Predicted ratio of risk (Rc /Rp ) for breast cancer incidence for the 6 HL patients
receiving scanned carbon versus scanned proton therapy when α/β for the HL target was
6 Gy (left) and 10 Gy (right) and α/β for the breast was 1 Gy (top), 3 Gy (middle), and
5 Gy (bottom). The various data points in each plot represent the kp and kc values for our
sensitivity testing described in Chapter 4. The mean and standard deviation of (Rc /Rp )
for all points are annotated for each plot. Importantly, our findings are seen to have only
minimal dependence on the exact value of α/β for the HL target in the range of 6-10 Gy.
However, strong dependence on the exact α/β value for the breast is seen in the range of
1-5 Gy.
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Figure B.2: Predicted ratio of risk (Rc /Rp ) for breast cancer incidence for the 6 HL patients
receiving scanned carbon versus scanned proton therapy when 5-mm radial beam margins
are added to mitigate uncertainty in patient setup. α/β for the HL target was 8 Gy and
α/β for the breast was 3 Gy. The various data points in each plot represent the kp and kc
values for our sensitivity testing described in Chapter 4. For all points here, (Rc /Rp ) was
0.81±0.36. Increasing the radial beam margin increased the amount of breast tissue exposed
to radiation for both proton therapy and carbon-ion therapy. However, we observed less
than a 5% difference in our mean predicted risk ratios between these calculations including
radial margins and those calculations presented in Chapter 4, which did not include margins
for patient setup errors (cf. Figure 4.12).
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